



CURRICULUM VITAE

Christopher J. Logothetis, M.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Roy M. and Phyllis Gough Huffington Clinical Research in Urologic Oncology Distinguished Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Director, The David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3438
Phone: 713-563-7210
Fax: 713-792-1654

EDUCATION

Degree-Granting Education

University of Athens School of Medicine, Athens, Greece, MD, 1974, Medicine

Postgraduate Training

Clinical Internship, Cook County Hospital, Chicago, IL, 1974-1975

Clinical Residency, Cook County Hospital, Chicago, IL, 1975-1977

Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX, 1977-1979

CREDENTIALS

Board Certification

American Board of Internal Medicine, 1978

Medical Oncology Subspecialty Board, 1981

Licensures

Active

Texas Medical Board, TX, F2328, 1978-5/2018

DPS, B0046882, 1978-8/2016

DEA, AL1440053, 1978-3/2019

Inactive

N/A

EXPERIENCE/SERVICE

Academic Appointments

Instructor in Medicine, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1979-1980

Assistant Internist, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1980-1983

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1980-1984

Associate Internist, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1983-1987

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1984-1992

Chief, Section of Genitourinary Medical Oncology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1986-1993

Internist, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1987-present

Consultant in Oncology, Texas Medical Foundation, Houston, TX, 1989-present

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1992-present

Adjunct Professor, Center for Biotechnology, Baylor College of Medicine, Houston, TX, 1993-1995

Administrative Appointments/Responsibilities

Physician Advisor, The University of Texas MD Anderson Cancer Center, Houston, TX, 1989-present

Division of Medicine Promotions Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 1991-present

Co-Chairman, Annual Genitourinary Oncology Conference, The University of Texas MD Anderson Cancer Center Annual Genitourinary Oncology Conference, Houston, TX, 1993-present

Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993-present

Credentials Committee for the Medical Staff, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1993

Co-Chairman, European-American Conference on Urological Diseases Medical Liaison for International Patient Center, Houston, TX, 1994-present

Chairman, Station 19 Work Group, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1994

Co-Director, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Prostate Cancer Research Program, Houston, TX, 1996-present

Director, Genitourinary Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002-2015

Administrative Director, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2002-present

Director, The David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-present

Other Appointments/Responsibilities

Expert Foreign Referee, Athens Medical School Review Committee, Athens, Greece, 3/2014-present

Endowed Positions

Bessie McGoldrick Professorship in Clinical Cancer Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1994-2002

Roy M. and Phyllis Gough Huffington Clinical Research in Urologic Oncology Distinguished Chair, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002-present

Consultantships

Bristol-Myers Squibb, Jersey City, NJ, Consultant, CRPC Advisory Board Meeting, 3/2014

Millennium, The Takeda Oncology Company, Boston, MA, Consultant, Prostate Cancer Global Strategic Advisory Board, 4/2014

Novartis, Prague, Czech Republic, Consultant, New Therapeutic Indications for LEE011 Prostate Cancer Advisory Board, 4/2014

Helsinn Healthcare SA, Switzerland, Consultant, Scientific Advice on Investigational New Drug in mCRPC, 5/2014-9/2014

Bayer Oncology, Whippany, NJ, Consultant, Bone Metastasis Working Group, 10/2014

Janssen Pharmaceutica NV, Lisbon, Portugal, Consultant, Prostate Cancer Debate Meeting by remote video link, 10/2014

National Cancer Institute, Rockville, MD, Consultant, Prostate Cancer Provocative Questions Workshop, 11/2014

Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., Rosemont, IL, Consultant, Experts Round Table Meeting, 12/2014

Moffitt Cancer Center, Tampa, FL, Consultant, External Review of GU Program, 6/2015

Churchill Pharmaceuticals, Chicago, IL, Consultant, Prostate Cancer Advisory Board Member Meeting, 10/2015

Astellas Medical Affairs, Americas and Medivation, Inc., Washington, DC, Consultant, Precision Medicine and Biomarkers in Prostate Cancer Advisory Board, 10/2015

Clovis Oncology, Inc., Washington, DC, Consultant, Clovis Oncology Prostate Cancer Advisory Board, 10/2015

Sanofi Oncology, Boston, MA, Advisor, Expert Faculty on Prostate Cancer Meeting, 12/2015

Astellas Pharma US, Inc and Medivation, Inc, San Francisco, CA, Consultant, XTANDI (enzalutamide) capsules Advisory Board, 1/2016

Sanofi US Services Inc., New Orleans, LA, Advisor, Proselica & Firstana Global Medical Affairs Advisory Board, 4/2016

Arno Therapeutics, Santa Monica, CA, Consultant, Onapristone Prostate Cancer Advisory Board, 5/2016

Northwestern Memorial Hospital, Chicago, IL, Consultant, SPORE in Prostate Cancer External Advisory Board, 9/2016

Sanofi US Services Inc, Boston, MA, Advisor, Expert Faculty on Prostate Cancer AB, 12/2016

Roswell Park Cancer Institute, Buffalo, NY, Advisor, External Advisory Board Meeting, 12/2016

Global Medical Affairs Oncology (Bayer), Whippany, NJ, Consultant, Xofigo Non-Interventional Study (REASSURE) Steering Committee Meeting, 12/2016

Churchill Pharmaceuticals, Dallas, TX, Consultant, Churchill Pharmaceuticals Oncology Advisory Board, 3/2017

Janssen Pharmaceuticals, Philadelphia, PA, Consultant, Platform Study Protocol Writing Meeting, 8/2017

Military or Other Governmental Service

N/A

Institutional Committee Activities

DoCM Advisory Committee, Member, 1993-present

DoCM Executive Council, Member, 1993-present

Epidemiology Chair Search Committee, Chair, 2007-present

Moon Shots Program Steering Committee, Member, 2012-present

Institutional Research Executive Committee (IREC), Member, 2013-present

Brain Tumor SPORE, Internal Advisory Board Member, 9/2013-present

MD Anderson Breast Cancer SPORE, Internal Advisory Board Member, 8/2016-present

MD Anderson Kidney SPORE, Internal Advisory Board Member, 1/2017-present

Research Council

EPAC Committee

Clinical Faculty Review Committee

HONORS AND AWARDS

Clifton D. Howe Fellowship Achievement Award, The University of Texas MD Anderson Cancer Center, 1979

Excellence in Teaching Clinical Oncology Award, The University of Texas M. D. Anderson Cancer Center Medical Oncology Fellows, 1992

CaP CURE Award, The Prostate Cancer Foundation, 1993-2003

The University Cancer Foundation Faculty Achievement Award in Patient Care, The University of Texas MD Anderson Cancer Center, 1998

Donald S. Coffey Prostate Cancer Foundation Physician/Scientist Award, Prostate Cancer Foundation, 2005

Division of Cancer Medicine Hematology/Oncology Fellowship Program Teaching Department of the Year, The University of Texas MD Anderson Cancer Center, 2010

Challenge Award, Prostate Cancer Foundation, 2011

Director's Service Award, National Cancer Institute, 2011

Division of Cancer Medicine John Mendelsohn Lifetime Scientific Achievement Award, The University of Texas MD Anderson Cancer Center, 2012

PCF-Special Challenge Award, Prostate Cancer Foundation, 2014

Charles A. LeMaistre, M.D., Outstanding Achievement Award in Cancer, The University of Texas MD Anderson Cancer Center, 2015

Division of Cancer Medicine Hematology/Oncology Fellowship Program Distinguished Alumnus Award, The University of Texas MD Anderson Cancer Center, 2015

The Finneran Family Prize in Translational Research, William B. Finneran, 2015

RESEARCH

Grants and Contracts

Funded

Program Leader, GU Cancers Program, 10%, Cancer Center Support (CORE) Grant - Genitourinary Cancers Program, 5 P30 CA016672-38, NIH/NCI, PI - DePinho, 9/6/2013-6/30/2018, \$115,010 (\$11,501/year)

Collaborator, 1%, Mechanisms of de Novo and Acquired Resistance to Therapeutic Treatment of Bone-Metastatic Prostate Cancer, RP150282, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Gallick, 3/1/2015-2/28/2018, \$855,000 (\$285,000/year)

Collaborator, 1%, Regulation of Dormancy of Metastatic Prostate Cancer Cells by Bone Microenvironment, RP150179, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Lin, 3/1/2015-2/28/2018 (\$285,000/year)

Principal Investigator, 1%, Expansion of Stanford Alexander Tissue Derivatives Laboratory, The Stanford and Joan Alexander Fam Fund, 4/14/2015-4/13/2020, \$1,000,000 (\$200,000/year)

Co-Principal Investigator, 1%, Identifying Markers for Early Prediction of Prostate Cancer Bone Metastases in Prostate Cancer from Analyses of the Tumor-Associated Microenvironments, Prostate Cancer Foundation, PI - Logothetis/Gallick, 2/1/2016-1/31/2018, \$500,000 (\$250,000/year)

Multiple Principal Investigator; Clinical Co-Leader, Project 3 (0.60 CM); Administrative Core (1.20 CM); Co-Director, DRP (0.30 CM); Co-Director, CEP (0.30 CM), MD Anderson Cancer Center Prostate Cancer SPORE, 2 P50 CA140388-06A1, NIH/NCI, PI - Logothetis/Thompson, 9/1/2016-8/31/2021 (\$1,412,349/year)

Pending

Co-Investigator, 2%, Standardized Quantitative Imaging Biomarkers for Co-Clinical Trials, U24 CA220280, NIH/NCI, PI - Hazle, 7/1/2017-6/30/2022 (\$554,842/year)

Principal Investigator, 0.36 months, Lipidomics-based Biomarkers for Risk of Progression in Early Prostate Cancer, R21 CA223527-01, NIH/NCI, 9/1/2017-8/31/2019

Co-Investigator, 3%, Patient-Derived Models of Prostate Cancer for Personalized Medicine, U01, NIH/NCI, PI - Navone/Futreal, 12/1/2017-11/30/2022 (\$848,987/year)

Other

N/A

Completed

Mentor, Paul Calabresi Clinical Oncology Research Career Development Program, 5 K12 CA088084-15, NIH/NCI, PI - Bast, 9/1/2000-8/31/2015 (\$594,690/year)

Principal Investigator, 1%, A Phase I/II Open Label Dose Escalation Study of the 17alpha Hydroxylase/C17, 20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer (COU-A-002), 2007-0583, Cougar Biotechnology, 2/4/2008-9/21/2015

Principal Investigator, 1%, A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy, CS2008-00024137JW, Cougar Biotechnology, 6/6/2008-2/11/2013 (\$528,800/year)

Principal Investigator, 1%, A Phase 3 Ct, Randomized, Double Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer, 2009-0168, Cougar Biotechnology, 6/2/2009-4/30/2017

Principal Investigator, 1%, A Randomized, Open Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone (COU-AA-203), 2009-0322 (Project 968453), Cougar Biotechnology, 6/19/2009-6/30/2017 (\$537,600/year)

Principal Investigator, 5%, MD Anderson Cancer Center Prostate Cancer Research Program Clinical Consortium Award, W81XWH-09-1-0148, Department of Defense (DOD), 9/1/2009-8/31/2015, \$1,000,000 (\$200,000/year)

Principal Investigator, 10%, MD Anderson Cancer Center Prostate Cancer SPORE Core A: Administrative Core, 5 P50 CA140388-05, NIH/NCI, 9/2/2009-8/31/2016 (\$195,541/year)

Principal Investigator, 1%, A Study of Continuous Oral Dosing of a Novel Antiandrogen MDV3100, in Castration-Resistant Bone Metastatic Prostate Cancer Patients Evaluating the Tumor Micro-Environment, CS2010-0031189IG01, Medivation, 3/1/2010-6/1/2015 (\$762,953/year)

Principal Investigator, 1%, An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who have Progressed After Taxane-Based Chemotherapy, CS2011-00034562LG-01, Cougar Biotechnology/Johnson & Johnson, 3/27/2011-3/26/2016 (\$186,795/year)

Principal Investigator, 5%, Mechanisms of Resistance to Androgen Biosynthesis Inhibition in Castrate-Resistant Prostate Cancer Bone Metastases, PCF - Special Challenge Award, 6/1/2011-5/31/2013, \$1,000,000 (\$500,000/year)

Principal Investigator, 1%, Stanford and Joan Alexander Tissue Derivatives Fund, The Stanford and Joan Alexander Foundation, 3/12/2012-3/11/2015, \$545,454 (\$181,818/year)

Principal Investigator, 1%, A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (formerly MDV3100) in Combination with Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients (9785-CL-0011), 2012-0083 (Project 969389), Astellas Pharma US Inc., 6/13/2012-6/12/2017 (\$79,466/year)

Principal Investigator, 1%, A Phase 3b Multicenter, Open-Label Abiraterone Acetate Long-term Safety Study, 212082-PCR-3010, Johnson and Johnson, 6/26/2012-6/26/2014 (\$25,736/year)

Co-Principal Investigator, Prostate Cancer Moon Shot: Integrated Plan for Reducing Mortality of Advanced Prostate Cancer Flagship Project 2: Establish concepts for advancement of biomarker-driven clinical trials for treatment-refractory prostate cancer, MD Anderson Moon Shot Program, PI - Logothetis/Thompson, 9/20/2012-8/31/2015 (\$1,074,484/year)

Co-Principal Investigator, Prostate Cancer Moon Shot: Integrated Plan for Reducing Mortality of Advanced Prostate Cancer, MD Anderson Moon Shot Program, PI - Logothetis/Thompson, 9/20/2012-8/31/2016 (\$1,389,377/year)

MPI, 1%, A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination with Abiraterone Acetate and Prednisone in Patients with Prostate Cancer who have PSA Progression after Prostatectomy and/or Radiotherapy, 2012-0993, Janssen Biotech, PI - Logothetis-Lin-Gallick, 1/30/2013-1/29/2016 (\$101,353/year)

Project Co-Leader, 5%, MD Anderson Cancer Center Prostate SPORE Project 2: Osteocrines in Therapy Resistance of Prostate Cancer Bone Metastasis, 5 P50 CA140388-05, NIH/NCI, 9/2/2013-2/28/2015 (\$160,413/year)

Principal Investigator, 1%, A Pre-Op Study to Assess the Effects of Abiraterone Acetate + LHRH Agonist and Abiraterone, 2013-0332 (Project 1258), Janssen Biotech, Inc., 9/24/2013-8/31/2016, \$995,332

Co-Principal Investigator, 1%, Osteocrines in Therapy Resistance of Prostate Cancer Bone Metastasis: Evaluation of Strategies to Overcome Therapy Resistance from Tumor-Educated Bone Environment, PCF-Janssen Special Challenge Award, PI - Logothetis/Lin/Gallick, 4/4/2014-10/4/2016, \$273,750 (\$138,750/year)

Co-Principal Investigator, Prostate Cancer Moon Shot: Integrated Plan for Reducing Mortality of Advanced Prostate Cancer, MD Anderson Moon Shot Program, PI - Logothetis/Thompson, 9/1/2014-8/31/2015 (\$1,989,818/year)

Co-Principal Investigator, Prostate Cancer Moon Shot: Integrated Plan for Reducing Mortality of Advanced Prostate Cancer Flagship Project 1: Adaptive androgen signaling in mCRPC effectively targeted by novel androgen signaling inhibitors., MD Anderson Moon Shot Program, PI - Logothetis/Thompson, 9/1/2014-8/31/2015 (\$661,170/year)

Director, Administrative Core, MD Anderson Cancer Center Prostate Cancer SPORE – Administrative Core, Bridge Funding/MD Anderson - Internal Funding, 3/1/2015-2/29/2016, \$65,659

Co-Principal Investigator, 0.6 months, Flagship 1: Optimizing Androgen Signaling Inhibition to Transition from a Treatment to Curative Paradigm, PCa Moon Shot, MD Anderson Moon Shot Program, PI - Logothetis/Thompson, 9/1/2016-8/31/2017 (\$1,377,800/year)

Co-Principal Investigator, 0.6 months, Flagship 2: Targeting the Immune and Non-Immune Tumor-Associated Microenvironments in Prostate Cancer, PCa Moon Shot, MD Anderson Moon Shot Program, PI - Logothetis/Thompson, 9/1/2016-8/31/2017 (\$621,103/year)

Not Funded

N/A

Protocols

Funded

Principal Investigator, EFSTATHIOU Levels of Androgens and IGF in Bone Marrow Versus Peripheral Blood in Hormonally Ablated Prostate Cancer Patients. Exploratory Assessment of Potential Correlation with Bone Metastasis, LAB07-0335, 2007-present, MDACC

Principal Investigator, A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate plus LHRHa Versus LHRHa Alone. (COU-AA-203), 2009-0322, 2009-present, Cougar Biotechnology

Principal Investigator, A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients with Locally Advanced Adenocarcinoma of the Prostate, 2009-0473, 2010-present, NCI

Principal Investigator, Maximal Androgen Depletion Followed by Serial Randomization of Maximal Androgen Ablation with Molecular Targeted Therapies, 2010-0070, 2011-present, BMS, MDACC, Pfizer, Janssen Scientific Affairs LLC

Principal Investigator, A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (formerly MDV3100) in Combination with Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients (9785-CL-0011), 2012-0083, 2012-present, Astellas Pharma Global Development

Principal Investigator, A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study (212082PCR3010), 2012-0530, 2012-present, Janssen Research & Development

Principal Investigator, A Pre-Operative Study to Assess the Effects of Abiraterone acetate plus LHRH Agonist and Abiraterone acetate plus LHRH Agonist and Enzalutamide for Six Months for Prostate Cancer Patients at High-risk for Recurrence, 2013-0332, 2013-present, MDACC, Medivation, Janssen Scientific Affairs, LLC

Principal Investigator, A Metabolic Pathway Activation Marker for Prostate Cancer Prognosis, PA15-0947, 2016-present, NIH

Principal Investigator, EVALUATION OF CIRCULATING TUMOR CELLS IN SOLID TUMOR MALIGNANCIES, PA15-0956, 2016-present, DOD

Unfunded

Principal Investigator, SCREENING PHAGE DISPLAY RANDOM PEPTIDE LIBRARIES IN HUMANS, ID99-417, 2000-2014

Principal Investigator, An Observational Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone, in Castration Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma, 2007-0590, 2007-2014, Cougar Biotechnology

Principal Investigator, A Phase I/II Open Label Dose Escalation Study of the 17 Hydroxylase/C17, 20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer., 2007-0583, 2007-2015, \$201,124, DOD, Cougar Biotech

Principal Investigator, A Study of Continuous Oral Dosing of a Novel Antiandrogen MDV3100, in Castration-Resistant Bone Metastatic Prostate Cancer Patients Evaluating the Tumor Micro-Environment, 2009-0886, 2009-2014, Medivation

Principal Investigator, A Limited, First-in-Man, Phase IB Evaluation of BMTP-11 in Patients with Castrate-Resistant Prostate Cancer with High-Volume Osseous Metastases and no Standard Treatment Options, 2008-0395, 2009-2015, MDACC

Principal Investigator, A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer, 2009-0168, 2009-2015, Cougar Biotechnology

Principal Investigator, Receptor Status of Indolent vs Active Disseminated Tumor Cells, DR10-0456, 2009-present

Principal Investigator, A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer, 2014-0538, 2014-2015, Janssen Research & Development, LLC

Principal Investigator, Meta-analysis Of bone targeting RadioPharmacEutical therapy in patients with bone metastasis from Prostate cancer, PA15-0938, 2016-present

Patents and Technology Licenses

Patents

Lin S-H., Luo W. and Logothetis CJ, C-CAM as an Angiogenesis Inhibitor, United States, UTMDACC-UTSC:623PZ1,

Chung L., Chan J., Logothetis CJ., and Hsieh J-T, Novel Bone and Prostate-Derived Protein Factors Affecting Prostate Cancer Growth, Differentiation, and Metastasis, United States, PCT/SU5/00094/U.S. Serial No. 08/179,569/Reference No. Ke/he23-9, Filed

The University of Texas System, Novel Bone and Prostate-Derived Protein Factors Affecting Prostate Cancer Growth, Differentiation, and Metastasis, United States, 14489/95/PCT/US95/00094/08/179,569, Filed

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

Landon Foundation-AACR INNOVATOR Award in Research in Tumor Microenvironment, AACR, Member, 2014

Movember Translation Acceleration Grant 2: Novel Therapeutics for Advanced Disease, Prostate Cancer Canada, Chair, 2014

NCI Program Project Meeting II (P01), NIH, Member, 2014

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Trindade A, Samuels ML, Logothetis CJ. Chemotherapy of carcinoma of renal pelvis: preliminary report. *Urology* 18(1):54-9, 7/1981. PMID: 6894814.
2. Logothetis CJ, Samuels ML, Wallace S, Chuang V, Trindade A, Grant C, Haynie TP, 3rd, Johnson DE. Management of pelvic complications of malignant urothelial tumors with combined intra-arterial and iv chemotherapy. *Cancer Treat Rep* 66(7):1501-7, 7/1982. PMID: 7046931.
3. Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. *Cancer* 50(8):1629-35, 10/1982. PMID: 6288220.

4. Logothetis CJ, von Eschenbach AC, Samuels ML, Trindade A, Johnson DE. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report. *Cancer Treat Rep* 66(1):57-63, 1982. PMID: 7053267.
5. Logothetis CJ, Samuels ML, Trindade A. The management of brain metastases in germ cell tumors. *Cancer* 49(1):12-8, 1982. PMID: 6274499.
6. Logothetis CJ, Samuels ML, von Eschenbach AC, Trindade A, Ogden S, Grant C, Johnson DE. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. *J Clin Oncol* 1(6):368-79, 6/1983. PMID: 6422006.
7. Libshitz HI, Jing BS, Wallace S, Logothetis CJ. Sterilized metastases: a diagnostic and therapeutic dilemma. *AJR Am J Roentgenol* 140(1):15-9, 1983. PMID: 6600307.
8. Bracken RB, Johnson DE, Frazier OH, Logothetis CJ, Trindade A, Samuels ML. The role of surgery following chemotherapy in stage III germ cell neoplasms. *J Urol* 129(1):39-43, 1983. PMID: 6298475.
9. Logothetis CJ, Samuels ML. Surgery in the management of stage III germinal cell tumors. Observations on the M.D. Anderson Hospital experience, 1971-1979. *Cancer Treat Rev* 11(1):27-37, 3/1984. PMID: 6203643.
10. Rusch VW, Logothetis C, Samuels M. Endodermal sinus tumor of the mediastinum. Report of apparent cure in two patients with extensive disease. *Chest* 86(5):745-7, 11/1984. PMID: 6207993.
11. Logothetis CJ, Samuels ML, Trindade A, Grant C, Gomez L, Ayala A. The prognostic significance of endodermal sinus tumor histology among patients treated for stage III nonseminomatous germ cell tumors of the testes. *Cancer* 53(1):122-8, 1984. PMID: 6317156.
12. Logothetis CJ, Samuels ML, Selig DE, Dexeus FH, Johnson DE, Swanson DA, von Eschenbach AC. Chemotherapy of extragonadal germ cell tumors. *J Clin Oncol* 3(3):316-25, 3/1985. PMID: 2579212.
13. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. *J Clin Oncol* 3(3):326-35, 3/1985. PMID: 2579213.
14. Logothetis CJ, Newell GR, Samuels ML. Testicular cancer in homosexual men with cellular immune deficiency: report of 2 cases. *J Urol* 133(3):484-6, 3/1985. PMID: 2579253.
15. Dexeus F, Logothetis CJ, Samuels ML, Hossan E, von Eschenbach AC. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. *Cancer Treat Rep* 69(7-8):885-6, 7/1985. PMID: 4016795.
16. Logothetis CJ, Samuels ML, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. *Urology* 26(3):252-5, 9/1985. PMID: 3929441.
17. Logothetis CJ, Samuels ML, Ogden S, Dexeus FH, Swanson D, Johnson DE, von Eschenbach A. Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases. *J Urol* 134(3):460-4, 9/1985. PMID: 2993671.
18. Logothetis CJ, Samuels ML, Selig DE, Johnson DE, Swanson DA, von Eschenbach AC. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. *J Urol* 134(6):1127-30, 12/1985. PMID: 2414470.
19. Logothetis CJ, Samuels ML, Selig DE, Wallace S, Johnson DE. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors. *Cancer Treat Rep* 69(1):33-8, 1985. PMID: 2981619.
20. Logothetis CJ. Perioperative chemotherapy for the management of primary local regional urothelial tumors. *Prog Clin Biol Res* 201:359-66, 1985. PMID: 3841594.
21. Logothetis CJ. Preoperative chemotherapy in the treatment of germinal tumors. *Prog Clin Biol Res* 201:341-50, 1985. PMID: 2419920.

22. Dexeus F, Logothetis C, Hossan E, Samuels ML. Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. *J Urol* 136(2):403-7, 8/1986. PMID: 2426474.
23. Logothetis CJ, Samuels ML, Selig DE, Ogden S, Dexeus F, Swanson D, Johnson D, von Eschenbach A. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. *Am J Med* 81(2):219-28, 8/1986. PMID: 2426944.
24. Dexeus FH, Logothetis C, Samuels ML, Hossan B. Phase II study of spirogermanium in metastatic prostate cancer. *Cancer Treat Rep* 70(9):1129-30, 9/1986. PMID: 3742495.
25. Chong C, Logothetis CJ, von Eschenbach A, Ayala A, Samuels M. Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response. *J Urol* 136(6):1221-3, 12/1986. PMID: 3022018.
26. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. *Cancer* 59(10):1803-9, 5/1987. PMID: 3030528.
27. Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, von Eschenbach AC, Johnson DE, Samuels ML. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. *J Clin Oncol* 5(6):906-11, 6/1987. PMID: 2438389.
28. Sella A, Logothetis CJ, Ro JY, Swanson DA, Samuels ML. Sarcomatoid renal cell carcinoma. A treatable entity. *Cancer* 60(6):1313-8, 9/1987. PMID: 2441841.
29. Logothetis CJ, Samuels ML, Ogden SL, Dexeus FH, Chong CD. Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patients. *J Urol* 138(4):789-94, 10/1987. PMID: 3656535.
30. Dexeus FH, Logothetis CJ, Samuels ML, Ayala AG, Hossan E. Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens. *J Urol* 137(1):122-5, 1987. PMID: 3795354.
31. Floyd C, Ayala AG, Logothetis CJ, Silva EG. Spermatocytic seminoma with associated sarcoma of the testis. *Cancer* 61(2):409-14, 1/1988. PMID: 3334976.
32. Chong CD, Logothetis CJ, von Eschenbach AC, Ayala AG, Samuels ML. Successful treatment of pure endodermal sinus tumors in adult men. *J Clin Oncol* 6(2):303-7, 2/1988. PMID: 2448426.
33. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Ogden S, von Eschenbach A, Ayala A. Adjuvant chemotherapy of bladder cancer: a preliminary report. *J Urol* 139(6):1207-11, 6/1988. PMID: 3373589.
34. Dexeus FH, Logothetis CJ, Chong C, Sella A, Ogden S. Genetic abnormalities in men with germ cell tumors. *J Urol* 140(1):80-4, 7/1988. PMID: 2837589.
35. Chong CD, Logothetis CJ, Savaraj N, Fritsche HA, Gietner AM, Samuels ML. The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. *J Clin Pharmacol* 28(8):714-8, 8/1988. PMID: 3216038.
36. Dunphy CH, Ayala AG, Swanson DA, Ro JY, Logothetis C. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. *Cancer* 62(6):1202-6, 9/1988. PMID: 2842034.
37. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, Smith T, Swanson DA, Babaian RJ, Wishnow KI, et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. *J Clin Oncol* 6(10):1590-6, 10/1988. PMID: 3171626.
38. Shirkhoda A, Dexeus FH, Logothetis CJ. Clinical and radiologic staging of locally advanced and inoperable bladder carcinoma. *J Comput Tomogr* 12(4):298-302, 10/1988. PMID: 3197433.
39. Tetu B, Ro JY, Ayala AG, Ordonez NG, Logothetis CJ, von Eschenbach AC. Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome. *Urology* 33(2):148-52, 2/1989. PMID: 2536972.
40. Sella A, Dexeus FH, Chong C, Ro JY, Logothetis CJ. Radiation therapy-associated invasive bladder tumors. *Urology* 33(3):185-8, 3/1989. PMID: 2919477.

41. Dexeus FH, Logothetis CJ, Sella A, Finn L. Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. *Am J Clin Oncol* 12(4):350-4, 8/1989. PMID: 2667326.
42. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, Pilat S. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. *J Urol* 141(1):33-7, 1989. PMID: 2908950.
43. Dexeus FH, Shirkhoda A, Logothetis CJ, Chong C, Sella A, Ogden S, Swanson D. Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapy. *Eur J Cancer Clin Oncol* 25(1):35-43, 1989. PMID: 2920767.
44. Dexeus FH, Logothetis CJ, Sella A, Fitz K, Amato R, Reuben JM, Dozier N. Phase II study of coumarin and cimetidine in patients with metastatic renal cell carcinoma. *J Clin Oncol* 8(2):325-9, 2/1990. PMID: 2137163.
45. Logothetis CJ. The case for relevant staging of germ cell tumors. *Cancer* 65(3):709-17, 2/1990. PMID: 2154316.
46. Logothetis CJ, Dexeus FH, Sella A, Amato RJ, Kilbourn RG, Finn L, Gutterman JU. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. *J Natl Cancer Inst* 82(8):667-72, 4/1990. PMID: 2181151.
47. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. *J Clin Oncol* 8(6):1050-5, 6/1990. PMID: 2189954.
48. Gutterman J, Vadhan-Raj S, Logothetis C, Anaissle E, Estey E, Talpaz M, Kurzrock R. Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense. *Semin Hematol* 27(3):15-24, 7/1990. PMID: 2198660.
49. Sella A, Logothetis CJ, Dexeus FH, Amato R. Chemotherapy immediately after surgery for patients with germ cell tumors. *Urology* 36(3):264-6, 9/1990. PMID: 2168105.
50. Logothetis CJ, Chong C, Dexeus FH, Sella A, Ogden S. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors. *Prog Clin Biol Res* 350:301-7, 1990. PMID: 1696741.
51. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ogden S. The impact of chemotherapy on the survival of patients with metastatic urothelial tumors. *Prog Clin Biol Res* 350:107-14, 1990. PMID: 2201037.
52. Dexeus FH, Kilbourn R, Chong C, Logothetis CJ, Sella A, Grignon D. Association of germ cell tumors and Hodgkin's disease. *Urology* 37(2):129-34, 2/1991. PMID: 1846990.
53. Logothetis CJ, Hossan E, Sella A, Dexeus FH, Amato RJ. Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. *J Natl Cancer Inst* 83(4):285-8, 2/1991. PMID: 1994058.
54. Sella A, Logothetis CJ, Dexeus FH, Amato R, Finn L, Fitz K. Cisplatin combination chemotherapy for elderly patients with urothelial tumours. *Br J Urol* 67(6):603-7, 6/1991. PMID: 2070205.
55. Dexeus FH, Logothetis CJ, Sella A, Fitz K, Striegel A, Amato RJ, Liu FJ. Serum biomarkers in metastatic renal cell carcinoma. *Urology* 38(1):6-10, 7/1991. PMID: 1714107.
56. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Ogden S, Striegel A, Kwan J, Newman RA. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. *J Urol* 146(3):709-13, 9/1991. PMID: 1831513.
57. Logothetis CJ. Organ preservation in bladder carcinoma: a matter of selection. *J Clin Oncol* 9(9):1525-6, 9/1991. PMID: 1875215.
58. Sella A, el Naggari A, Ro JY, Dexeus FH, Amato RJ, Lee JS, Finn L, Logothetis CJ. Evidence of malignant features in histologically mature teratoma. *J Urol* 146(4):1025-8, 10/1991. PMID: 1680200.
59. Dimopoulos MA, Amato RJ, Logothetis CJ. Predictive factors for effective salvage therapy of nonseminomatous germ cell tumors of testis. *Urology* 38(4):351-4, 10/1991. PMID: 1661457.

60. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Fitz K, Striegel A. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. *J Urol* 146(5):1284-7, 11/1991. PMID: 1719241.
61. Grignon DJ, Ro JY, Ayala AG, Shum DT, Ordonez NG, Logothetis CJ, Johnson DE, Mackay B. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. *Cancer* 69(2):527-36, 1/1992. PMID: 1309435.
62. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. *J Urol* 147(3):935-7, 3/1992. PMID: 1311396.
63. Giralt SA, Dexeus F, Amato R, Sella A, Logothetis C. Hyperthyroidism in men with germ cell tumors and high levels of beta-human chorionic gonadotropin. *Cancer* 69(5):1286-90, 3/1992. PMID: 1371235.
64. Sella A, Logothetis CJ, Fitz K, Dexeus FH, Amato R, Kilbourn R, Wallace S. Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. *J Urol* 147(3):573-7, 3/1992. PMID: 1538431.
65. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, Benedict WF. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. *J Natl Cancer Inst* 84(16):1256-61, 8/1992. PMID: 1640485.
66. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. *Cancer Res* 52(24):6940-4, 12/1992. PMID: 1458483.
67. Logothetis CJ. Chemotherapy resistant transitional cell carcinoma as a target for chemoprevention. *J Cell Biochem Suppl* 16I:128-31, 1992. PMID: 1305675.
68. Chung LW, Li W, Gleave ME, Hsieh JT, Wu HC, Sikes RA, Zhou HE, Bandyk MG, Logothetis CJ, Rubin JS, et al. Human prostate cancer model: roles of growth factors and extracellular matrices. *J Cell Biochem Suppl* 16H:99-105, 1992. PMID: 1289680.
69. Sella A, Amato RJ, Fitz K, Kilbourn RG, Logothetis, CJ. Interferon-alpha and 5-fluorouracil Combination Chemotherapy for Metastatic Renal Cell Cancer. *Inter and Cyto* 20, 1992. PMID: 1538431.
70. Wishnow KI, Levinson AK, Johnson DE, Tenney DM, Grignon DJ, Ro JY, Ayala AJ, Logothetis CJ, Swanson DA, Babaian RJ, et al. Stage B (P2/3A/N0) transitional cell carcinoma of bladder highly curable by radical cystectomy. *Urology* 39(1):12-6, 1992. PMID: 1728789.
71. Dimopoulos MA, Logothetis CJ, Markowitz A, Sella A, Amato R, Ro J. Collecting duct carcinoma of the kidney. *Br J Urol* 71(4):388-91, 4/1993. PMID: 8499979.
72. Hoosein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. *J Urol* 149(5):1209-13, 5/1993. PMID: 8097794.
73. Sella A, Swanson DA, Ro JY, Putnam JB, Jr, Amato RJ, Markowitz AB, Logothetis CJ. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. *J Urol* 149(1):19-21; discussion 21-2, 1993. PMID: 8417208.
74. Dimopoulos MA, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. *J Urol* 151(3):598-600; discussion 600-1, 3/1994. PMID: 8308966.
75. Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothetis CJ. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. *J Clin Oncol* 12(4):683-8, 4/1994. PMID: 7512126.
76. Logothetis CJ, Hossan E, Recondo G, Sella A, Ellerhorst J, Kilbourn R, Zukiwski A, Amato R. 5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen. *Anticancer Res* 14(3B):1265-9, 5/1994. PMID: 8067694.
77. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. *Anticancer Res* 14(3A):1215-20, 5/1994. PMID: 8074475.
78. Ellerhorst JA, Kilbourn RG, Amato RJ, Zukiwski AA, Jones E, Logothetis CJ. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. *J Urol* 152(3):841-5, 9/1994. PMID: 8051732.

79. Mitropoulos D, Dimopoulos MA, Kiroudi-Voulgari A, Zervas A, Dimopoulos C, Logothetis CJ. Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinoma. *J Urol* 152(4):1124-6, 10/1994. PMID: 8072080.
80. Logothetis CJ, Hoosein NM, Hsieh JT. The clinical and biological study of androgen independent prostate cancer (AI PCa). *Semin Oncol* 21(5):620-9, 10/1994. PMID: 7524155.
81. Crawford ED, Kozlowski JM, Debruyne FM, Fair WR, Logothetis CJ, Balmer C, Robinson RG, Porter AT, Kirk D. The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. *Urology* 44(4):481-5, 10/1994. PMID: 7524233.
82. Logothetis CJ, Hossan EA, Smith TL. SMS 201-995 in the treatment of refractory prostatic carcinoma. *Anticancer Res* 14(6B):2731-4, 11/1994. PMID: 7872709.
83. Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ, Logothetis CJ. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. *Cancer Biother* 9(2):103-11, 1994. PMID: 7812360.
84. Fornage BD, Logothetis CJ, Swanson DA, Ro JY. Bilateral testicular metastases from prostate carcinoma: gray-scale and color Doppler sonographic findings. *J Ultrasound Med* 14(3):247-9, 3/1995. PMID: 7760471.
85. Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ. The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. *J Urol* 153(5):1587-91, 5/1995. PMID: 7536271.
86. Sternberg CN, Raghaven D, Ohi Y, Bajorin D, Herr H, Kato T, Kuroda M, Logothetis CH, Scher H, Splinter TA. Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis? *Int J Urol* 2(2):76-88, 6/1995. PMID: 7553308.
87. Kilbourn RG, Fonseca GA, Griffith OW, Ewer M, Price K, Striegel A, Jones E, Logothetis CJ. NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. *Crit Care Med* 23(6):1018-24, 6/1995. PMID: 7774211.
88. Tu SM, Robinson ED, Amato RJ, Ellerhorst JA, Kilbourn RG, Logothetis CJ. A phase I study of FAP (5-Fluorouracil, α -interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignancies. *Urol Oncol* 1(4):156-60, Jul-Aug, 7/1995. PMID: 21224110.
89. Hoosein NM, Martin KJ, Abdul M, Logothetis CJ, Kaddurah-Daouk R. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells. *Anticancer Res* 15(4):1339-42, 7/1995. PMID: 7654018.
90. Amato RJ, Ellerhorst J, Bui C, Logothetis CJ. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. *Urol Oncol* 1(4):168-72, Jul-Aug, 7/1995. PMID: 21224113.
91. Abdul M, Logothetis CJ, Hoosein NM. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. *J Urol* 154(1):247-50, 7/1995. PMID: 7776439.
92. Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. *J Clin Oncol* 13(9):2272-7, 9/1995. PMID: 7666085.
93. Amato R, Meyers C, Ellerhorst J, Finn L, Kilbourn R, Sella A, Logothetis C. A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. *Ann Oncol* 6(9):911-4, 11/1995. PMID: 8624294.
94. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. *J Urol* 154(5):1719-22, 11/1995. PMID: 7563331.
95. Amato RJ, Ellerhorst J, Banks M, Logothetis CJ. Carboplatin and ifosfamide and selective consolidation in advanced seminoma. *Eur J Cancer* 31A(13):2223-8, 12/1995. PMID: 8652247.
96. Hoosein, N, Abdul M, McCabe R, Gero E, Deftos L, Banks M, Hodges S, Finn L, Logothetis CJ. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. *Urologic Oncology* 1(6):246-51, 1995. PMID: 21224126.

97. Hsieh, JT, Wu HC, Wang Y, Song WT, Li W, Finn L, Logothetis CJ. Evidence for the existence of an organ-specific androgen-independent pathway of progression in patients with metastatic prostate cancer. *Urologic Oncology* 1(2):67-72, 1995. PMID: 21224094.
98. Nazario, A, Amato RJ, Hutchinson L, Bui C, Ellerhorst J, Logothetis CJ. Paclitaxel in extensively pretreated nonseminomatous germ cell tumors. *Urologic Oncology* 1(5):184-7, 1995. PMID: 21224115.
99. Sella A, Aggarwal BB, Kilbourn RG, Bui CA, Zukiwski AA, Logothetis CJ. Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer. *Cancer Biother* 10(3):225-35, 1995. PMID: 8547961.
100. Abdul, M, Hsieh J-T, Logothetis CJ, Hoosein NM. Secretion of prostate-specific antigen-suppressing activity by two human prostate carcinoma cell lines. *Urologic Oncology* 1(1):38-41, 1995. PMID: 21224088.
101. Herrada J, Dieringer P, Logothetis CJ. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal. *J Urol* 155(2):620-3, 2/1996. PMID: 8558675.
102. Logothetis C, Swanson D, Amato R, Banks M, Finn L, Ayala A, Ro J, Babaian R, Dinney C, Ellerhorst J, Hall C, von Eschenbach A. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. *J Urol* 155(4):1241-5, 4/1996. PMID: 8632540.
103. Hutter RV, Montie JE, Busch C, Crignon DJ, Lieber M, Logothetis C, Ragde H, Reuter VE. Current prognostic factors and their relevance to staging. *Cancer* 78(2):369-71, 7/1996. PMID: 8674020.
104. Sim SJ, Glassman AB, Ro JY, Lee JJ, Logothetis CJ, Liu FJ. Serum calcitonin in small cell carcinoma of the prostate. *Ann Clin Lab Sci* 26(6):487-95, 11/1996. PMID: 8908318.
105. Tu SM, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ. Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. *Urol Oncol* 2(6):191-7, Nov-Dec, 11/1996. PMID: 21224168.
106. Amato, RJ, Ellerhorst J, Finn L, Logothetis CJ. Absence of anti-tumor activity with Prednisone in patients with progressive androgen-independent prostate carcinoma. *Urologic Oncology* 2(2):70-3, 1996. PMID: 21224139.
107. Logothetis CJ. Chemotherapy for invasive and metastatic bladder cancer. *Advances in Oncology* 12(1):19-22, 1996.
108. Hoosein, N, Abdul M, Logothetis CJ. Significance of neuroendocrine differentiation in prostatic carcinoma. *The Cancer Journal* 9(6):291-295, 1996.
109. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. *J Urol* 157(2):569-74, 2/1997. PMID: 8996359.
110. Chaturvedi V, Li L, Hodges S, Johnston D, Ro JY, Logothetis C, von Eschenbach AC, Batsakis JG, Czerniak B. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. *Oncogene* 14(17):2059-70, 5/1997. PMID: 9160886.
111. Hu SX, Ji W, Zhou Y, Logothetis C, Xu HJ. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. *Cancer Res* 57(16):3339-43, 8/1997. PMID: 9269991.
112. Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. *Oncology (Williston Park)* 11(11A):180-93, 11/1997. PMID: 9430189.
113. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. *Clin Cancer Res* 3(12 Pt 1):2493-500, 12/1997. PMID: 9815652.
114. Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. *Cancer* 80(11):2128-32, 12/1997. PMID: 9392335.

115. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. *Clin Cancer Res* 3(12 Pt 1):2371-6, 12/1997. PMID: 9815636.
116. Logothetis CJ. Biologic foundation of the therapy for advanced germ cell tumors. *Semin Urol Oncol* 16(2):62-4, 5/1998. PMID: 9649228.
117. Tu SM, Pagliaro LC, Banks ME, Amato RJ, Millikan RE, Bugazia NA, Madden T, Newman RA, Logothetis CJ. Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer. *Clin Cancer Res* 4(5):1193-201, 5/1998. PMID: 9607577.
118. Millikan RE, Logothetis CJ. Prospects for optimized clinical management of bladder cancer by application of phenotypic markers. *J Natl Cancer Inst* 90(14):1028-9, 7/1998. PMID: 9672249.
119. Logothetis CJ. Emerging strategies in the treatment of testis cancer. *Curr Opin Urol* 8(5):411-2, 9/1998. PMID: 17039021.
120. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. *Cancer Genet Cytogenet* 106(2):105-9, 10/1998. PMID: 9797773.
121. Herrmann JL, Briones F, Jr, Brisbay S, Logothetis CJ, McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. *Oncogene* 17(22):2889-99, 12/1998. PMID: 9879995.
122. Moss, TJ, Logothetis CJ, Wood CG. Immunocytochemical (ICC) analysis: An attractive alternative to reverse transcriptase-polymerase chain reaction (RT-PCR) in molecular staging of prostate cancer (PCa). *J Urol* 159(5):292, 1998.
123. Ozen M, Hopwood VL, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S. Aneuploidy index in blood: a potential marker for early onset, androgen response, and metastasis in human prostate cancer. *Urology* 53(2):381-5, 2/1999. PMID: 9933059.
124. Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. *Oncogene* 18(5):1185-96, 2/1999. PMID: 10022124.
125. Amato RJ, Bui C, Logothetis CJ. Estramustine in combination with vinblastine and mitomycin-C for patients with progressive androgen independent adenocarcinoma of the prostate. *Prostate Cancer Prostatic Dis* 2(2):83-87, 3/1999. PMID: 12496843.
126. Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. *Br J Cancer* 79(9):1588-93, 3/1999. PMCID: PMC2362736.
127. Park DS, Prow DM, Amato RJ, Ro JY, Logothetis CJ. Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic era. *Yonsei Med J* 40(2):137-43, 4/1999. PMID: 10333717.
128. Luo W, Tapolsky M, Earley K, Wood CG, Wilson DR, Logothetis CJ, Lin SH. Tumor-suppressive activity of CD66a in prostate cancer. *Cancer Gene Ther* 6(4):313-21, 7/1999. PMID: 10419049.
129. Logothetis CJ. Introduction: a therapeutically relevant framework for the classification of human prostate cancer. *Semin Oncol* 26(4):369-74, 8/1999. PMID: 10482179.
130. Park DS, Prow DM, Amato RJ, Logothetis CJ. Management consideration in nonpulmonary visceral metastatic seminoma of testis. *J Korean Med Sci* 14(4):431-7, 8/1999. PMCID: PMC3054405.
131. Pisters LL, Pettaway CA, Hossan E, Evans R, Steiner MS, Wood CG, Troncoso P, McDonnell TJ, Fenstenmacher MJ, Logothetis CJ. Intraprostatic AD-p53 gene therapy followed by radical prostatectomy: feasibility and preliminary results. *Prostate Cancer Prostatic Dis* 2(S3):S27, 11/1999. PMID: 12496806.
132. McCutcheon IE, Eng DY, Logothetis CJ. Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. *Cancer* 86(11):2301-11, 12/1999. PMID: 10590371.

133. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. *J Urol* 161(1):304-8, 1999. PMID: 10037428.
134. Lin SH, Pu YS, Luo W, Wang Y, Logothetis CJ. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model. *Anticancer Res* 19(1A):337-40, 1999. PMID: 10226564.
135. Pettaway CA, Pisters LL, Troncoso P, Slaton J, Finn L, Kamoi K, Logothetis CJ. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. *J Clin Oncol* 18(5):1050-7, 3/2000. PMID: 10694556.
136. Navone NM, Rodriguez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. *Clin Cancer Res* 6(3):1190-7, 3/2000. PMID: 10741751.
137. Kim J, Palmer JL, Finn L, Hodges S, Bowes VV, Deftos L, Murphy G, Logothetis C. The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate. *Urol Oncol* 5(3):97-103, 4/2000. PMID: 10765015.
138. Ozen M, Hopwood VL, Balbay MD, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S. Correlation of non-random chromosomal aberrations in lymphocytes of prostate cancer patients with specific clinical parameters. *Int J Oncol* 17(1):113-7, 7/2000. PMID: 10853027.
139. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. *Cancer* 89(3):615-8, 8/2000. PMID: 10931461.
140. Lecrone V, Li W, Devoll RE, Logothetis C, Farach-Carson MC. Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. *Cell Calcium* 27(1):35-42, 2000. PMID: 10726209.
141. Amato RJ, Millikan R, Daliani D, Wood L, Logothetis C, Pollack A. Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. *Clin Cancer Res* 6(1):72-7, 2000. PMID: 10656434.
142. Schumacher G, Bruckheimer EM, Beham AW, Honda T, Brisbay S, Roth JA, Logothetis C, McDonnell TJ. Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. *Int J Cancer* 91(2):159-66, 1/2001. PMID: 11146439.
143. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. *Lancet* 357(9253):336-41, 2/2001. PMID: 11210994.
144. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. *Clin Cancer Res* 7(5):1198-203, 5/2001. PMID: 11350884.
145. Millikan R, Baez L, Banerjee T, Wade J, Edwards K, Winn R, Smith TL, Logothetis C. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. *Urol Oncol* 6(3):111-115, 5/2001. PMID: 11344001.
146. Millikan RE, Plunkett WK, Smith TL, Williams DL, Logothetis CJ. Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. *Cancer* 92(1):194-9, 7/2001. PMID: 11443627.
147. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. *Cancer Res* 61(14):5652-9, 7/2001. PMID: 11454720.
148. Fizazi K, Amato RJ, Beuzeboc P, Petit N, Bouhour D, Thiss A, Rebuschung C, Chevreau C, Logothetis CJ, Droz JP. Germ cell tumors in patients infected by the human immunodeficiency virus. *Cancer* 92(6):1460-7, 9/2001. PMID: 11745223.
149. Honda T, Gjertsen BT, Spurgers KB, Briones F, Lee SJ, Hobbs ML, Meyn RE, Roth JA, Logothetis C, McDonnell TJ. Restoration of bax in prostate cancer suppresses tumor growth

- and augments therapeutic cell death induction. *Anticancer Res* 21(5):3141-6, 9/2001. PMID: 11848465.
150. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. *Cancer Chemother Pharmacol* 48(4):319-26, 10/2001. PMID: 11710633.
 151. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, Williams D, Logothetis C. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. *J Clin Oncol* 19(20):4005-13, 10/2001. PMID: 11600601.
 152. Millikan, RE, Baez L, Banerjee T, Wade J, Edwards K, Winn R, Smith TL, Logothetis C. Randomized phase 2 trial of ketoconazole and ketoconazole /doxorubicin in androgen independent prostate cancer. *Urologic Oncology* 6(3):111-115, 2001. PMID: 11344001.
 153. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. *Cancer Lett* 176(1):57-63, 2/2002. PMID: 11790454.
 154. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardeli PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R. Steps toward mapping the human vasculature by phage display. *Nat Med* 8(2):121-7, 2/2002. PMID: 11821895.
 155. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Jr, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. *J Clin Oncol* 20(5):1361-7, 3/2002. PMID: 11870180.
 156. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. *Clin Cancer Res* 8(3):775-81, 3/2002. PMID: 11895908.
 157. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. *Br J Cancer* 86(10):1555-60, 5/2002. PMID: PMC2746595.
 158. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P, Logothetis CJ. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. *Cancer* 94(10):2610-7, 5/2002. PMID: 12173328.
 159. Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. *J Clin Oncol* 20(13):2965-70, 7/2002. PMID: 12089226.
 160. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. *J Clin Oncol* 20(14):3072-80, 7/2002. PMID: 12118020.
 161. Logothetis CJ. Challenge of locally persistent prostate cancer: an unresolved clinical dilemma. *J Clin Oncol* 20(15):3187, 8/2002. PMID: 12149287.
 162. Pu YS, Do KA, Luo W, Logothetis CJ, Lin SH. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. *Anticancer Drugs* 13(7):743-9, 8/2002. PMID: 12187331.
 163. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. *Carcinogenesis* 23(8):1289-96, 8/2002. PMID: 12151346.

164. Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH. Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. *J Biol Chem* 277(38):35696-702, 9/2002. PMID: 12122002.
165. Fizazi K, Do KA, Wang X, Finn L, Logothetis CJ, Amato RJ. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial. *Ann Oncol* 13(1):125-34, 2002. PMID: 11863094.
166. Pu, Y-S, Do K-A, Luo W, Logothetis CJ, Lin S-H. Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. *Anti-Cancer Drugs* 13:1-8, 2002.
167. Coombes KR, Zhang L, Bueso-Ramos C, Brisbay S, Logothetis C, Roth J, Keating MJ, McDonnell TJ. TAD: a web interface and database for tissue microarrays. *Appl Bioinformatics* 1(3):155-8, 2002. PMID: 15130842.
168. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. *Nat Biotechnol* 21(1):57-63, 1/2003. PMID: 12496764.
169. Pentz RD, Flamm AL, Pasqualini R, Logothetis CJ, Arap W. Revisiting ethical guidelines for research with terminal wean and brain-dead participants. *Hastings Cent Rep* 33(1):20-6, 1/2003. PMID: 12613384.
170. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. *Urol Oncol* 21(1):21-6, 1/2003. PMID: 12684123.
171. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. *Cancer* 97(3):561-7, 2/2003. PMID: 12548597.
172. Logothetis C, Tu SM, Navone N. Targeting prostate cancer bone metastases. *Cancer* 97(3):785-8, 2/2003. PMID: 12548576.
173. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. *J Natl Cancer Inst* 95(6):458-70, 3/2003. PMID: 12644539.
174. Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J, 3rd, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. *J Clin Oncol* 21(5):878-83, 3/2003. PMID: 12610188.
175. Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C, McDonnell TJ. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. *J Urol* 169(4):1553-7, 4/2003. PMID: 12629413.
176. Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ. A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. *Cancer* 97(12):2988-94, 6/2003. PMID: 12784333.
177. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. *Clin Cancer Res* 9(7):2587-97, 7/2003. PMID: 12855635.
178. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. *Mol Cancer Ther* 2(9):835-43, 9/2003. PMID: 14555702.
179. Logothetis CJ. Foundation for the integration of biologically based therapy in the management of prostate cancer. *Prostate* 57(1):32-8, 9/2003. PMID: 12886521.
180. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). *Urol Oncol* 21(5):342-8, 9/2003. PMID: 14670540.

181. Zurita AJ, Troncoso P, Cardo-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. *Cancer Res* 64(2):435-9, 1/2004. PMID: 14744752.
182. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. *J Urol* 171(1):145-8, 1/2004. PMID: 14665863.
183. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol* 22(3):537-56, 2/2004. PMID: 14752077.
184. Spurgers KB, Coombes KR, Meyn RE, Gold DL, Logothetis CJ, Johnson TJ, McDonnell TJ. A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells. *Oncogene* 23(9):1712-23, 3/2004. PMID: 14647426.
185. Mathew P, Fidler IJ, Logothetis CJ. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. *Semin Oncol* 31:24-9, 4/2004. PMID: 15176001.
186. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. *Clin Cancer Res* 10(8):2587-93, 4/2004. PMID: 15102659.
187. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. *J Biol Chem* 279(18):19191-200, 4/2004. PMID: 14985354.
188. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. *J Clin Oncol* 22(11):2108-21, 6/2004. PMID: 15169797.
189. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. *Cancer Res* 64(15):5036-43, 8/2004. PMID: 15289299.
190. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. *J Clin Oncol* 22(16):3323-9, 8/2004. PMID: 15310776.
191. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ, Pettaway CA, Shete S, Spitz MR, Logothetis CJ. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. *Prostate* 60(4):343-51, 9/2004. PMID: 15264247.
192. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. *Anticancer Res* 24(5A):2897-903, 9/2004. PMID: 15517894.
193. Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis CJ, Troncoso P, Papandreou CN, McDonnell TJ. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. *Clin Cancer Res* 10(20):6770-8, 10/2004. PMID: 15501953.
194. Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, Droz JP, Logothetis CJ. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. *J Clin Oncol* 22(19):3868-76, 10/2004. PMID: 15302906.
195. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and

- agonist effects in normal and malignant prostate cells. *Cancer Epidemiol Biomarkers Prev* 13(11 Pt 1):1710-6, 11/2004. PMID: 15533897.
196. Wyatt RB, Sanchez-Ortiz RF, Wood CG, Ramirez E, Logothetis C, Pettaway CA. Prognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancer. *J Natl Med Assoc* 96(12):1587-93, 12/2004. PMID: PMC2568655.
 197. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. *Neoplasia* 7(3):280-93, 3/2005. PMID: PMC1501140.
 198. Cho-Vega JH, Troncso P, Do KA, Rago C, Wang X, Tsavachidis S, Medeiros LJ, Spurgers K, Logothetis C, McDonnell TJ. Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. *Mod Pathol* 18(4):577-84, 4/2005. PMID: 15529182.
 199. Kim J, Sun P, Lam YW, Troncso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. *Cancer Epidemiol Biomarkers Prev* 14(7):1697-702, 7/2005. PMID: 16030104.
 200. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. *Cancer Res* 65(14):6189-98, 7/2005. PMID: 16024620.
 201. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncso P. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. *Clin Cancer Res* 11(19 Pt 1):6889-94, 10/2005. PMID: 16203779.
 202. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. *J Clin Oncol* 23(32):8232-41, 11/2005. PMID: 16278478.
 203. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. *J Clin Oncol* 23(31):7904-10, 11/2005. PMID: 16258090.
 204. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. *J Urol* 174(6):2186-90, 12/2005. PMID: 16280761.
 205. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. *J Natl Cancer Inst* 98(11):783-93, 6/2006. PMID: 16757703.
 206. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. *Oncogene* 25:6015-25, 9/2006. PMID: 16682954.
 207. Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ, McDonnell TJ. Identification of Cell Cycle Regulatory Genes as Principal Targets of p53-mediated Transcriptional Repression. *J Biol Chem* 281(35):25134-42, 9/2006. PMID: 16798743.
 208. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. *Clin Genitourin Cancer* 5(2):144-9, 9/2006. PMID: 17026803.
 209. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-

- dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. *Cancer* 107:2254-61, 11/2006. PMID: 17029276.
210. Wang J, Do KA, Wen S, Tsavachidis S, McDonnell TJ, Logothetis CJ, Coombes KR. Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer. *Cancer Inform* 2:87-97, 2006. e-Pub 2/2007. PMCID: PMC2675498.
 211. Efsthathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. *Clin Cancer Res* 13(4):1224-31, 2/2007. PMID: 17317833.
 212. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer (Review). *Cancer Immun* 7:10 (Review), 6/2007. PMCID: PMC2935746.
 213. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. A Secreted Isoform of ErbB3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer Cells. *Cancer Res* 67(14):6544-8, 7/2007. PMCID: PMC2000837.
 214. van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C. The VIOXX in prostate cancer prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. *Curr Med Res Opin* 23(9):2063-2070, 7/2007. PMID: 17651539.
 215. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. *Oncogene* 27(5):596-603, 8/2007. PMID: 17700537.
 216. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. *Clin Cancer Res* 13(19):5816-24, 10/2007. PMID: 17908974.
 217. Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. *J Natl Cancer Inst* 99(21):1613-22, 11/2007. e-Pub 10/2007. PMID: 17971530.
 218. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S, Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. *Lancet Oncol* 8(11):994-1000, 11/2007. e-Pub 10/2007. PMID: 17942366.
 219. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. *Stat Med* 26(26):4687-702, 11/2007. e-Pub 4/2007. PMID: 17427204.
 220. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. *Prostate* 67(15):1677-85, 11/2007. PMID: 17879948.
 221. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: Key to the effective treatment of prostate cancer. *Clin Cancer Res* 14(6):1599-602, 3/2008. PMID: 18347159.
 222. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. *Oncogene* 27(39):5195-203, 5/2008. PMCID: PMC2562662.
 223. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. *Clin Cancer Res* 14(12):3729-36, 6/2008. PMCID: PMC2562877.
 224. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efsthathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human

- prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. *J Clin Invest* 118(8):2697-710, 7/2008. PMID: PMC2447924.
225. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ, Lin SH. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. *Mol Cancer Res* 6(8):1259-67, 8/2008. PMID: PMC2643879.
 226. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFN γ -producing CD4+ICOS γ cells to shift the ratio of effector to regulatory T cells in cancer patients. *Proc Natl Acad Sci U S A* 105(39):14987-92, 9/2008. PMID: 18818309.
 227. Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. *Int J Cancer* 124(1):1-6, 9/2008. PMID: 18942061.
 228. Mathew P, Thall PF, Wen S, Bucana C, Jones D, Horne E, Oh WK, Morris MJ, Lee YC, Logothetis CJ, Lin SH, Fidler IJ. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. *Br J Cancer* 99(9):1426-32, 10/2008. PMID: PMC2579696.
 229. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2 α -dependent renal cancer tumorigenesis. *Cancer Biol Ther* 7(10):1619-27, 10/2008. e-Pub 10/2008. PMID: 19018165.
 230. McDonnell TJ, Chari NS, Cho-Vega JH, Troncso P, Wang X, Bueso-Ramos CE, Coombes K, Brisbay S, Lopez R, Prendergast G, Logothetis C, Do KA. Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. *BMC Med Genomics* 1:1, 2008. e-Pub 1/2008. PMID: PMC2227949.
 231. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. *Clin Genitourin Cancer* 7(1):51-7, 1/2009. PMID: PMC3394090.
 232. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOS γ T cell frequency and IFN- γ levels in both nonmalignant and malignant prostate tissues. *Proc Natl Acad Sci U S A* 106(8):2729-34, 2/2009. e-Pub 2/2009. PMID: PMC2650334.
 233. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn P. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. *Cancer Biol Ther* 8(3):245-52, 2/2009. PMID: PMC2854203.
 234. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. *J Natl Cancer Inst* 101(5):306-20, 2/2009. PMID: PMC2734116.
 235. Gnjjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells. *Clin Cancer Res* 15(6):2130-9, 3/2009. PMID: 19276258.
 236. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. *J Clin Oncol* 27(20):3319-3324, 7/2009. PMID: PMC4371137.
 237. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. *BMC Med Genomics* 2:48, 8/2009. PMID: PMC2731785.
 238. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. *BJU Int* 104(4):456-60, 8/2009. PMID: 19338544.
 239. Araujo JC, Poblentz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-

- induced osteoclast formation. *Cancer Biol Ther* 8(22):2151-7, 11/2009. PMID: PMC4073296.
240. Byun J, Logothetis CJ, Gorlov IP. Housekeeping genes in prostate tumorigenesis. *Int J Cancer* 125(11):2603-8, 12/2009. PMID: PMC4531049.
 241. Gorlov IP, Gallick GE, Gorlova OY, Amos C, Logothetis CJ. GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. *PLoS One* 4(8):e6511, 2009. PMID: PMC2714961.
 242. Efstathiou E, Logothetis CJ. A new therapy paradigm for prostate cancer founded on clinical observations. *Clin Cancer Res* 16(4):1100-7, 2/2010. PMID: PMC3891669.
 243. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. *Prostate Cancer Prostatic Dis* 13(1):6-11, 3/2010. PMID: PMC2887695.
 244. Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality Therapy: Bone-targeted Radioisotope Therapy of Prostate Cancer. *Clin Adv Hematol Oncol* 8(5):341-51, 5/2010. PMID: PMC4993042.
 245. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. *Clin Cancer Res* 16(10):2861-71, 5/2010. PMID: PMC2919850.
 246. Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, Kim SM, Ortiz A, Wu FL, Logothetis CJ, Yu-Lee LY, Lin SH. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. *Cancer Res* 70(11):4580-9, 6/2010. PMID: PMC2923552.
 247. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic Characterization of Preoperatively Treated Prostate Cancer: Toward a Post-Therapy Histologic Classification. *Eur Urol* 57(6):1030-8, 6/2010. e-Pub 10/2009. PMID: PMC2962710.
 248. Zhao H, Logothetis CJ, Gorlov IP. Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression. *Prostate Cancer Prostatic Dis* 13(3):252-9, 9/2010. e-Pub 4/2010. PMID: PMC4136464.
 249. Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. *Cancer Treat Rev* 36(6):492-500, 10/2010. e-Pub 3/2010. PMID: PMC3940067.
 250. Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ, Alt EU. Adipose tissue-derived stem cells promote prostate tumor growth. *Prostate* 70(15):1709-15, 11/2010. e-Pub 6/2010. PMID: PMC4977846.
 251. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. *BMC Cancer* 10:599, 2010. e-Pub 11/2010. PMID: PMC2988752.
 252. Bracarda S, Logothetis C, Sternberg CN, Oudard S. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. *BJU Int* 107 Suppl 2:13-20, 4/2011. PMID: 21382150.
 253. Fitzpatrick JM, Bellmunt J, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A. Maximizing outcomes in genitourinary cancers across the treatment continuum. *BJU Int* 107 Suppl 2:1-12, 4/2011. PMID: 21382149.
 254. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med* 364(21):1995-2005, 5/2011. PMID: PMC3471149.
 255. Tzelepi V, Karlou M, Wen S, Hoang A, Logothetis C, Troncoso P, Efstathiou E. Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. *Histopathology* 58(7):1037-47, 6/2011. PMID: PMC4934422.

256. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. *Prostate* 71(8):846-56, 6/2011. e-Pub 11/2010. PMID: PMC3883511.
257. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment. *J Clin Oncol* 29(18):2574-81, 6/2011. e-Pub 5/2011. PMID: PMC3138635.
258. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bublely GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response. *Clin Cancer Res* 17(14):4854-61, 7/2011. e-Pub 6/2011. PMID: PMC3657705.
259. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. *J Natl Cancer Inst* 103(22):1665-1675, 11/2011. e-Pub 9/2011. PMID: PMC4176261.
260. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. *Sci Transl Med* 3(111):111ra121, 11/2011. PMID: PMC3476478.
261. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Mollndrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. *Proc Natl Acad Sci U S A* 108(46):18637-18642, 11/2011. e-Pub 11/2011. PMID: PMC3219136.
262. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. *Expert Opin Investig Drugs* 20(12):1677-84, 12/2011. e-Pub 10/2011. PMID: PMC4020016.
263. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5 α -reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. *PLoS One* 6(12):e28840, 2011. e-Pub 12/2011. PMID: PMC3237548.
264. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. *Ann Oncol* 23(1):46-52, 1/2012. e-Pub 4/2011. PMID: PMC3276320.
265. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. *Cancer* 118(1):63-71, 1/2012. e-Pub 7/2011. PMID: PMC3898168.
266. Ye X, Lee YC, Choueiri M, Chu K, Huang CF, Tsai WW, Kobayashi R, Logothetis CJ, Yu-Lee LY, Lin SH. Aberrant expression of katanin p60 in prostate cancer bone metastasis. *Prostate* 72(3):291-300, 2/2012. e-Pub 6/2011. PMID: PMC3179562.
267. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone. *J Clin Oncol* 30(6):637-43, 2/2012. e-Pub 12/2011. PMID: PMC3295561.
268. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features. *Clin Cancer Res* 18(3):666-77, 2/2012. e-Pub 12/2011. PMID: PMC3923417.
269. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Chow Maneval E, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-

- resistant prostate cancer: a phase 1/2 clinical trial. *Ann Oncol* 23(3):688-94, 3/2012. e-Pub 8/2011. PMID: PMC4415089.
270. Gorlov IP, Byun J, Zhao H, Logothetis CJ, Gorlova OY. Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with cancer development. *J Bioinform Comput Biol* 10(2):1241013, 4/2012. PMID: PMC3893106.
 271. Gorlov IP, Byun J, Logothetis CJ. In silico functional profiling of individual prostate cancer tumors: many genes, few functions. *Cancer Genomics Proteomics* 9(3):109-14, 5/2012. PMID: PMC3922615.
 272. Tu SM, Som A, Tu B, Logothetis CJ, Lee MH, Yeung SC. Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. *Br J Cancer* 107(4):646-51, 8/2012. e-Pub 7/2012. PMID: PMC3419961.
 273. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, for the COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol* 13(10):983-992, 10/2012. e-Pub 9/2012. PMID: 22995653.
 274. Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. *Br J Cancer* 107(9):1547-53, 10/2012. e-Pub 10/2012. PMID: PMC3493771.
 275. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothed inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. *Prostate* 72(15):1638-47, 11/2012. e-Pub 3/2012. PMID: PMC4977841.
 276. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. *Lancet Oncol* 13(12):1210-7, 12/2012. e-Pub 11/2012. PMID: 23142059.
 277. Gorlov IP, Logothetis CJ, Fang S, Gorlova OY, Amos C. Building a statistical model for predicting cancer genes. *PLoS One* 7(11):e49175, 2012. e-Pub 11/2012. PMID: PMC3499550.
 278. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways. *PLoS One* 7(12):e51189, 2012. e-Pub 12/2012. PMID: PMC3530555.
 279. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttman H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winkler E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med* 368(2):138-48, 1/2013. e-Pub 12/2012. PMID: PMC3683570.
 280. Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pistors LL, Maity S, Troncoso P, Logothetis CJ. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. *Prostate* 73(2):153-61, 1/2013. e-Pub 7/2012. PMID: PMC3878994.
 281. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. *Int J Radiat Oncol Biol Phys* 85(1):e39-46, 1/2013. e-Pub 10/2012. PMID: PMC3840533.

282. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. *J Clin Oncol* 31(4):412-9, 2/2013. e-Pub 11/2012. PMCID: PMC4110249.
283. Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ, Gallick GE, Lin SH. Targeting Constitutively Activated β 1 Integrin inhibits Prostate Cancer Metastasis. *Mol Cancer Res* 11(4):405-17, 4/2013. e-Pub 1/2013. PMCID: PMC3631285.
284. Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. *Prostate* 73(9):979-85, 6/2013. e-Pub 1/2013. PMCID: PMC4013833.
285. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. *Clin Cancer Res* 19(13):3621-30, 7/2013. e-Pub 5/2013. PMCID: PMC3699964.
286. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efsthathiou E, Lin SH. Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer. *Cancer Discov* 3(8):849-61, 8/2013. e-Pub 6/2013. PMCID: PMC3926428.
287. Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, Stagg LJ, Ladbury JE, Cai Z, Xu D, Logothetis CJ, Hung MC, Zhang S, Lin HK. Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression. *Cell* 154(3):556-68, 8/2013. PMCID: PMC3845452.
288. Autio KA, Bennett AV, Jia X, Fruscione M, Beer TM, George DJ, Carducci MA, Logothetis CJ, Kane RC, Sit L, Rogak L, Morris MJ, Scher HI, Basch EM. Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. *J Oncol Pract* 9(5):223-9, 9/2013. e-Pub 6/2013. PMCID: PMC3994234.
289. Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. *Int J Cancer* 133(7):1536-46, 10/2013. e-Pub 4/2013. PMCID: PMC3713179.
290. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. *Lancet Oncol* 14(12):1193-9, 11/2013. e-Pub 9/2013. PMID: 24075621.
291. Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI, COU-AA-301 Investigators. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. *Eur J Cancer* 49(17):3648-57, 11/2013. e-Pub 8/2013. PMID: 23973186.
292. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efsthathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. *Lancet Oncol* 14(13):1307-16, 12/2013. e-Pub 11/2013. NIHMSID: NIHM592540.
293. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efsthathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. *Cell* 155(6):1309-22, 12/2013. PMCID: PMC3932525.
294. Zhao H, Logothetis CJ, Gorlov IP, Zeng J, Dai J. Modified logistic regression models using gene coexpression and clinical features to predict prostate cancer progression. *Comput Math Methods Med* 2013:917502, 2013. e-Pub 12/2013. PMCID: PMC3866878.

295. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pistors LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. *Cancer Res* 74(6):1651-60, 3/2014. e-Pub 1/2014. PMID: PMC4009928.
296. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration-resistant prostate cancer. *Clin Cancer Res* 20(11):2846-50, 6/2014. e-Pub 4/2014. PMID: PMC4040316.
297. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 15(7):700-12, 6/2014. e-Pub 5/2014. PMID: 24831977.
298. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pistors LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. *J Natl Compr Canc Netw* 12(7):993-8, 7/2014. PMID: PMC4413899.
299. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeenan W, Kundra V, Wang F, Troncso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. *Sci Transl Med* 6(252):252ra122, 9/2014. PMID: PMC4407499.
300. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. *J Clin Oncol* 32(30):3391-9, 10/2014. e-Pub 9/2014. PMID: PMC4383838.
301. He Y, Gu J, Strom S, Logothetis CJ, Kim J, Wu X. The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients. *Clin Cancer Res* 20(19):5133-9, 10/2014. PMID: PMC4185411.
302. Bilen MA, Reyes A, Bhowmick D, Maa A, Bast R, Pistors LL, Lin SH, Logothetis CJ, Tu SM. Variant prostate carcinoma and elevated serum CA-125. *Can J Urol* 21(5):7442-8, 10/2014. PMID: PMC4400850.
303. Taplin ME, Montgomery B, Logothetis CJ, Bublely GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. *J Clin Oncol* 32(33):3705-15, 11/2014. e-Pub 10/2014. PMID: PMC4226804.
304. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). *Eur Urol* 66(5):815-25, 11/2014. e-Pub 3/2014. PMID: PMC4418928.
305. Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linossier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. *Lancet Oncol* 15(13):1442-50, 12/2014. e-Pub 11/2014. PMID: PMC4400870.

306. Gorlova O, Fedorov A, Logothetis C, Amos C, Gorlov I. Genes with a large intronic burden show greater evolutionary conservation on the protein level. *BMC Evol Biol* 14(1):50, 2014. e-Pub 3/2014. PMID: PMC3995522.
307. Gorlov IP, Yang JY, Byun J, Logothetis C, Gorlova OY, Do KA, Amos C. How to get the most from microarray data: advice from reverse genomics. *BMC Genomics* 15(1):223, 2014. e-Pub 3/2014. PMID: PMC3997969.
308. Efsthathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. *Eur Urol* 67(1):53-60, 1/2015. e-Pub 5/2014. PMID: PMC4247811.
309. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. *Cancer* 121(1):69-76, 1/2015. e-Pub 8/2014. PMID: PMC4270821.
310. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol* 16(2):152-60, 2/2015. e-Pub 1/2015. PMID: 25601341.
311. Mintz PJ, Rietz AC, Cardó-Vila M, Ozawa MG, Dondossola E, Do KA, Kim J, Troncoso P, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. *Proc Natl Acad Sci U S A* 112(8):2515-20, 2/2015. e-Pub 2/2015. PMID: PMC4345585.
312. Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. *Mol Cell Proteomics* 14(3):471-83, 3/2015. e-Pub 12/2014. PMID: PMC4349970.
313. Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. *Proc Natl Acad Sci U S A* 112(12):3776-81, 3/2015. e-Pub 3/2015. PMID: PMC4378428.
314. Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Griffin TW, Kheoh T, Ricci DS, Zelinsky K, Rathkopf DE, Scher HI, Ryan CJ. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. *Clin Cancer Res* 21(7):1621-7, 4/2015. e-Pub 1/2015. PMID: PMC4384987.
315. Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. *J Clin Oncol* 33(12):1356-63, 4/2015. e-Pub 1/2015. PMID: PMC4881370.
316. Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efsthathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. *Proc Natl Acad Sci U S A* 112(27):8403-8, 7/2015. e-Pub 6/2015. PMID: PMC4500257.
317. Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efsthathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W. Targeting the

- interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study. *Cancer* 121(14):2411-21, 7/2015. e-Pub 4/2015. PMID: PMC4490036.
318. Zurita AJ, Pisters LL, Wang X, Troncso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. *Prostate Cancer Prostatic Dis* 18(3):276-80, 9/2015. e-Pub 5/2015. PMID: PMC4821010.
319. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. *Eur Urol* 68(4):570-7, 10/2015. e-Pub 5/2015. PMID: 25985882.
320. Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, Hawke DH, Parikh NU, Varkaris A, Corn P, Logothetis C, Satcher RL, Yu-Lee LY, Gallick GE, Lin SH. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. *Cancer Res* 75(22):4949-59, 11/2015. e-Pub 11/2015. PMID: PMC4651787.
321. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. *Eur Urol* 68(5):850-8, 11/2015. e-Pub 7/2015. PMID: 26153564.
322. Tu H, Gu J, Meng QH, Kim J, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. *Oncotarget* 6(39):41988-96, 12/2015. PMID: PMC4747203.
323. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. *Clin Cancer Res* 22(1):107-21, 1/2016. e-Pub 8/2015. PMID: PMC4703437.
324. Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. *Neoplasia* 18(1):1-9, 1/2016. PMID: PMC4735600.
325. Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, Zhang J, Li-Ning-Tapia EM, Kapoor A, Wu CJ, Patel NB, Guo Z, Ramamoorthy V, Tieu TN, Heffernan T, Zhao D, Shang X, Khadka S, Hou P, Hu B, Jin EJ, Yao W, Pan X, Ding Z, Shi Y, Li L, Chang Q, Troncso P, Logothetis CJ, McArthur MJ, Chin L, Wang YA, DePinho RA. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. *Cancer Discov* 6(1):80-95, 1/2016. e-Pub 12/2015. PMID: PMC4707102.
326. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. *Clin Cancer Res* 22(6):1520-30, 3/2016. e-Pub 11/2015. PMID: PMC4794379.
327. Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. *BJU Int* 117(3):469-77, 3/2016. e-Pub 4/2015. PMID: PMC4547910.
328. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. *J Clin Oncol* 34(12):1402-18, 4/2016. e-Pub 2/2016. PMID: PMC4872347.
329. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS,

- Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. *J Clin Oncol* 34(14):1652-9, 5/2016. e-Pub 3/2016. PMID: PMC4872320.
330. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. *EBioMedicine* 7:85-93, 5/2016. e-Pub 4/2016. PMID: PMC4909608.
331. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. *Cancer* 122(12):1836-43, 6/2016. e-Pub 3/2016. PMID: PMC5071733.
332. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. *Oncotarget* 7(29):46321-46334, 7/2016. e-Pub 6/2016. PMID: PMC5216801.
333. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. *BJU Int* 118(1):68-76, 7/2016. e-Pub 7/2015. PMID: PMC4808616.
334. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. *Proc Natl Acad Sci U S A* 113(42):11919-11924, 10/2016. e-Pub 10/2016. PMID: PMC5081579.
335. Shu X, Ye Y, Gu J, He Y, Davis JW, Thompson TC, Logothetis CJ, Kim J, Wu X. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. *Carcinogenesis* 37(10):965-71, 10/2016. e-Pub 8/2016. PMID: PMC5035398.
336. Kuhn P, Carlsson A, Luttgren MS, Dizon KK, Troncoso P, Corn P, Kolatkar A, Hicks JB, Logothetis C, Zurita AJ. Paired high-content analysis of prostate cancer cells in bone marrow and blood characterizes increased androgen receptor expression in tumor cell clusters. *Clin Cancer Res*. e-Pub 10/2016. PMID: 27702818.
337. Ferrara F, Staquicini DI, Driessen WH, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. *Proc Natl Acad Sci U S A*. e-Pub 10/2016. PMID: PMC5111687.
338. Maity SN, Titus MA, Gyftaki R, Wu G, Lu JF, Ramachandran S, Li-Ning-Tapia EM, Logothetis CJ, Araujo JC, Efstathiou E. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. *Sci Rep* 6:35354, 10/2016. e-Pub 10/2016. PMID: PMC5066251.
339. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. *Oncotarget* 7(52):86280-86289, 12/2016. e-Pub 11/2016. PMID: PMC5349913.
340. Zhang T, Tseng C, Zhang Y, Sirin O, Corn PG, Li-Ning-Tapia EM, Troncoso P, Davis J, Pettaway C, Ward J, Frazier ML, Logothetis C, Kolonin MG. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. *Nat Commun* 7:11674, 2016. e-Pub 5/2016. PMID: PMC4895055.

341. Dayyani F, Zurita AJ, Noguerras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. *BMC Cancer* 16:721, 2016. e-Pub 9/2016. PMID: PMC5013640.
342. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, Piulats JM, Gonzalez Mella P, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, Carvajal R, Sengeløv L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. *J Clin Oncol* 35(1):40-47, 1/2017. e-Pub 10/2016. PMID: 28034081.
343. Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. *Oncol Lett* 13(3):1949-1957, 3/2017. e-Pub 1/2017. PMID: PMC5403694.
344. Aparicio A, Logothetis CJ. Reply to J.B. Aragon-Ching and D. Dalela et al. *J Clin Oncol* 35(8):917-918, 3/2017. e-Pub 12/2016. PMID: 27937088.
345. Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. *Sci Signal* 10(480), 5/2017. e-Pub 5/2017. PMID: 28536297.
346. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. *Nat Med* 23(5):551-555, 5/2017. e-Pub 3/2017. PMID: PMC5466900.
347. Lin SC, Lee YC, Yu G, Cheng CJ, Zhou X, Chu K, Murshed M, Le NT, Baseler L, Abe JI, Fujiwara K, deCrombrughe B, Logothetis CJ, Gallick GE, Yu-Lee LY, Maity SN, Lin SH. Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. *Dev Cell* 41(5):467-480.e3, 6/2017. PMID: PMC5512590.
348. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Dos Reis RB, Drake CG, Eeles R, Efstathiou E, Evans CP, Fantì S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khamli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *Eur Urol*. e-Pub 6/2017. PMID: 28655541.
349. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. *Cancer Chemother Pharmacol*. e-Pub 7/2017. PMID: 28730293.
350. Pezaro CJ, Omlin A, Mastris K, ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. *Ann Oncol* 28(8):1692-1694, 8/2017. PMID: 28838209.

Invited Articles

1. Logothetis CJ. CISCA Chemotherapy for bladder cancer. *Cancer Bulletin* 33(2):79-80, 3/1981.

2. Logothetis CJ, von Eschenbach A, Samuels ML, Trindade A, Johnson DE. DMF regimen for hormone-refractory adenocarcinoma of the prostate - The first 42 patients. *Cancer Bulletin* 34(1):26-28, 1982.
3. Logothetis CJ. Choriocarcinoma syndrome. *Cancer Bulletin* 36(2):118-120, 3/1984.
4. Logothetis CJ, Samuels M. Intra-arterial chemotherapy for malignant urothelial tumors. *Cancer Bulletin* 36(1):47-52, 1984.
5. Logothetis CJ. The lymphoma that wasn't. *World Journal of Urology* 2:73-75, 1984.
6. Logothetis CJ. The role of chemotherapy in the management of urothelial tumors: Interpretation of the M. D. Anderson Cancer Center results. *World Journal of Urology* 6(3):163-166, 12/1988.
7. Logothetis C. Treatment of chemotherapy-refractory metastatic urothelial tumors. *Urol Clin North Am* 19(4):775-7, 11/1992. PMID: 1441031.
8. Logothetis C, Hoosein N. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. *J Cell Biochem Suppl* 16H:128-34, 1992. PMID: 1337763.
9. Logothetis CJ, Amato RJ. Management of Residual Mass Following Effective Therapy for Seminoma, 3/1993.
10. Logothetis CJ. Chemotherapeutic approaches in advanced prostate cancer. *Oncology (Supplement)* 8(11):15-18, 1994.
11. Tu, S, Jones D, Finn L, Amato R, Ellerhorst J, Kilbourn R, Logothetis CJ. Strontium-89 (Str-89) combined with adriamycin (Adr) in the treatment of patients (pts) with androgen-independent prostate carcinoma (AI PCa), 6/1995.
12. Baker LH, Hanks G, Gershenson D, Kantoff P, Lange P, Logothetis C, Sandler H, Walsh P. NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. *Oncology (Williston Park)* 10(11 Suppl):265-88, 11/1996. PMID: 8953609.
13. Corral DA, Logothetis CJ. New approaches in the treatment of metastatic transitional-cell cancer of the bladder. *World J Urol* 15(2):139-43, 1997. PMID: 9144905.
14. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. *Cancer Metastasis Rev* 17(4):361-71, 1998. PMID: 10453280.
15. Gjertsen BT, Logothetis CJ, McDonnell TJ. Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. *Cancer Metastasis Rev* 17(4):345-51, 1998. PMID: 10453278.
16. Kim J, Logothetis CJ. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. *Urol Clin North Am* 26(2):281-90, 5/1999. PMID: 10361551.
17. Bahnsen RR, Hanks GE, Huben RP, Kantoff P, Kozlowski JM, Kuettel M, Lange PH, Logothetis C, Pow-Sang JM, Roach M, 3rd, Sandler H, Scardino PT, Taylor RJ, Urban DA, Walsh PC, Wilson TG. NCCN Practice Guidelines for Prostate Cancer. *Oncology (Williston Park)* 14(11A):111-9, 11/2000. PMID: 11195405.
18. Merritt JA, Roth JA, Logothetis CJ. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. *Semin Oncol* 28(5 Suppl 16):105-14, 10/2001. PMID: 11706402.
19. Logothetis CJ. Docetaxel in the Treatment of Prostate Cancer: Opportunities for Combination Regimens and Challenges to Development. . *Seminars in Oncology* 28(4):Supplement N, 2001.
20. Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. *Oncology (Williston Park)* 16(6 Suppl 6):63-72, 6/2002. PMID: 12108899.
21. Logothetis C, Millikan R. Docetaxel in the management of advanced or metastatic urothelial tract cancer. *Oncology (Williston Park)* 16(6 Suppl 6):107-11, 6/2002. PMID: 12108893.
22. Tu SM, Lin SH, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. *Lancet Oncol* 3(8):508-13, 8/2002. PMID: 12147437.
23. Logothetis CJ. A Framework for Rational and Accelerated Development of Therapy for Prostate Cancer. *Principles and Practice of Oncology* 16(6), 2002.
24. Logothetis CJ. The case for a biologically based classification of prostate cancer. *Semin Oncol* 30(5):562-6, 10/2003. PMID: 14571406.

25. Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA, National Comprehensive Cancer Network. Kidney cancer. Clinical practice guidelines. *J Natl Compr Canc Netw* 3(1):84-93, 1/2005. PMID: 19813325.
26. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. *Nat Rev Cancer* 5(1):21-8, 1/2005. PMID: 15630412.
27. Motzer RJ, Bahnon RR, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA, National Comprehensive Cancer Network. Testicular cancer. Clinical practice guidelines. *J Natl Compr Canc Netw* 3(1):52-76, 1/2005. PMID: 19813323.
28. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network. Kidney cancer. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 4(10):1072-81, 11/2006. PMID: 17112454.
29. Efsthathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. *J Natl Compr Canc Netw* 4(10):1059-70, 11/2006. PMID: 17112453.
30. Mohler J, Babaian RJ, Bahnon RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC, National Comprehensive Cancer Network. Prostate cancer. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 5(7):650-83, 8/2007. PMID: 17692170.
31. Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, Logothetis CJ. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. *J Clin Oncol* 26(36):5936-42, 12/2008. PMID: PMC3864402.
32. Efsthathiou E, Logothetis CJ. Prostate cancer: Thalidomide for prostate cancer: is there progress? *Nat Rev Urol* 6(5):248-50, 5/2009. PMID: 19424170.
33. Logothetis CJ. When 'dueling technologies' are mistaken for progress. *BJU Int* 107(11):1699-700, 6/2011. PMID: PMC3922611.
34. Logothetis CJ, Efsthathiou E, Manuguid F, Kirkpatrick P. Abiraterone acetate. *Nat Rev Drug Discov* 10(8):573-4, 8/2011. e-Pub 8/2011. PMID: 21804589.
35. Sharma P, Logothetis C. Prostate cancer: Combination of vaccine plus ipilimumab-safety and toxicity. *Nat Rev Urol* 9(6):302-3. e-Pub 5/2012. PMID: 22565371.
36. Chan CH, Jo U, Kohrman A, Rezaeian AH, Chou PC, Logothetis C, Lin HK. Posttranslational regulation of Akt in human cancer. *Cell Biosci* 4(1):59, 2014. e-Pub 10/2014. PMID: PMC4192732.
37. Gillissen S, Omlin A, Attard G, de Bono JS, Efsthathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol* 26(8):1589-604, 8/2015. e-Pub 6/2015. PMID: PMC4511225.

Editorials

1. Fizazi K, Chen I, Logothetis CJ. Germ-cell tumor survivors: the price for cure. *Ann Oncol* 13(2):187-9, 2/2002. PMID: 11885993.
2. Logothetis CJ, Millikan R. Chemotherapy for advanced prostate cancer: 25 years later. *J Clin Oncol* 26(15):2423-4, 5/2008. PMID: 18487561.
3. Logothetis CJ, Schellhammer PF. High-grade prostate cancer and the prostate cancer prevention trial. *Cancer Prev Res (Phila Pa)* 1(3):151-2, 5/2008. PMID: 19138948.

4. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation: a demanding taskmaster. *J Clin Oncol* 27(30):4937-8, 10/2009. PMID: 19720892.
5. Logothetis CJ, Siefker-Radtke A. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. *Eur Urol* 57(4):728-9, 4/2010. PMID: 20965043.
6. Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. *Cancer Discov* 1(6):466-8, 11/2011. PMCID: PMC4133693.
7. Kim J, Amos CI, Logothetis C. 5 α -Reductase inhibitors for prostate-cancer prevention. *N Engl J Med* 365(24):2340, 12/2011. PMID: 22168662.
8. Logothetis CJ. Treatment of prostate cancer metastases: more than semantics. *Lancet* 379(9810):4-6, 1/2012. e-Pub 11/2011. PMID: 22093188.
9. Logothetis CJ. Re: intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *Eur Urol* 64(1):170, 7/2013. PMID: 23746321.
10. Logothetis CJ. Treatment of castrate-resistant prostate cancer. *J Urol* 190(2):439-40, 8/2013. e-Pub 5/2013. PMID: 23707438.
11. Logothetis CJ. Prostate cancer bone metastases: not so systemic after all. *Lancet Oncol* 15(7):675-6, 6/2014. e-Pub 5/2014. PMID: 24836275.
12. Logothetis CJ, Aparicio AM. Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases? *J Clin Oncol* 34(24):2810-1, 8/2016. e-Pub 7/2016. PMID: 27432923.
13. Logothetis CJ. Improved Outcomes in Men with Advanced Prostate Cancer. *N Engl J Med* 377(4):388-390, 7/2017. PMID: 28745978.

Other Articles

1. Gillesen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Ann Oncol*. e-Pub 5/2016. PMID: 27141017.
2. Zhang X, Li B, Rezaeian AH, Xu X, Chou PC, Jin G, Han F, Pan BS, Wang CY, Long J, Zhang A, Huang CY, Tsai FJ, Tsai CH, Logothetis C, Lin HK. H3 ubiquitination by NEDD4 regulates H3 acetylation and tumorigenesis. *Nat Commun* 8:14799, 3/2017. e-Pub 3/2017. PMCID: PMC5357315.

Abstracts

1. Jeri Kim, John W. Davis, Eric A. Klein, Cristina Magi-Galluzzi, Yair Lotan, John F. Ward, Louis L. Pisters, Joseph W. Basler, Curtis A. Pettaway, Elsa M. Li Ning Tapia, Xuemei Wang, Kim-Anh Do, Jack Lee, Lana A. Vornik, Joe Tangrea, Howard L. Parnes, Scott M. Lippman, Ian M. Thompson, Powel H. Brown, Patricia Troncoso, Christopher J. Logothetis. A double-blind randomized controlled multisite trial evaluating tissue effects of preoperative finasteride in clinically organ-confined prostate cancer: Pathologic outcomes. *AACR (#LB-195)*, 2013.
2. Ana M. Aparicio, Sankar Maity, Xuemei Wang, Anh G. Hoang, Eleni Efstathiou, Patricia Troncoso, Christopher J. Logothetis. A molecular characterization of the anaplastic prostate carcinomas. *AACR (#1195)*, 2013.
3. Karim Fizazi, Lance C. Pagliaro, Aude Flechon, Jozef Mardiak, Lionnel Geoffrois, Pierre Kerbrat, Christine Chevreau, Remy Delva, Frederic Rolland, Christine Theodore, Guilhem Roubaud, Gwenaelle Gravis, Jean-Christophe Eymard, Jean-pierre Malhaire, Claude Linassier, Muriel Habibian, Florence Journeau, Christopher Logothetis, Stephane Culine, Agnes Laplanche. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13. *ASCO (#LBA4500)*, 2013.
4. Fred Saad; Neal D Shore; Hendrik Van Poppel; Dana Rathkopf; Matthew R. Smith; Johann S. de Bono; Christopher Logothetis; Paul de Souza; Karim Fizazi; Peter FA Mulders; Paul

- Mainwaring; John D Hainsworth; Tomasz M Beer; Scott North; Yves Fradet; Tom Griffin; Thian Kheoh; Eric J Small; Howard I Scher; Arturo Molina; Charles J Ryan. Abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy – Interim analysis of the COU-AA-302 phase 3 trial. AUA (#713), 2013.
5. Howard I. Scher, Matthew R. Smith, Christopher Sweeney, Paul Gettys Corn, Christopher Logothetis, Nicholas J. Vogelzang, David C. Smith, Maha Hussain, Daniel J. George, Johann Sebastian De Bono, Celestia S. Higano, Eric Jay Small, Jonathan Goldin, Matthew S. Brown, Dana T. Aftab, Mojtaba Noursalehi, Aaron Weitzman, Ethan M. Basch; Memorial Sloan-Kettering Cancer Center, New York, NY; Massachusetts General Hospital Cancer Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; Comprehensive Cancer Centers of Nevada, The US Oncology Network, Las Vegas, NV; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Duke Cancer Institute, Durham, NC; The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, San Francisco, San Francisco, CA; University of California, Los Angeles, Los Angeles, CA; Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, CA; Exelixis, Inc, South San Francisco, CA. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort. ASCO (#5026), 2013.
 6. Tomasz M. Beer, Christopher Logothetis, Padmanee Sharma, Yohann Lorient, Karim Fizazi, Alberto Bossi, Eugene D. Kwon, Brent McHenry, Paul Gagnier, Winald R. Gerritsen; Oregon Health & Science University Knight Cancer Institute, Portland, OR; The University of Texas MD Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, Villejuif, France; Mayo Clinic, Rochester, MN; Bristol-Myers Squibb, Wallingford, CT; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. CA184-095: A randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC). ASCO (#TPS5093), 2013.
 7. Amado J. Zurita, Farideh Z. Bischoff, Ivan Gorlov, Julie Ann Mayer, Tony J. Pircher, Steve Mikolajczyk, Christopher Logothetis, Sue-Hwa Lin; The University of Texas MD Anderson Cancer Center, Houston, TX; Biocept Inc., San Diego, CA. Cadherin-11 (Cad11) for detection of epithelial-mesenchymal transition (EMT) in circulating prostate cancer (PCa) cells. ASCO (#e22047), 2013.
 8. Ana M. Aparicio, Emily Gallichotte, Heather Cheng, Suk-Young Yoo, Sankar Maity, Christopher Logothetis, Muneesh Tewari. Circulating micro-RNAs can detect adaptive response to therapy and aggressive subset of prostate cancer. AACR (#1205), 2013.
 9. Jerome P. Richie; Robert B. Montgomery; Christopher J. Logothetis; Glenn J. Bubley; Bruce L. Dalkin; Martin G. Sanda; Massimo F. Loda; Rosina T. Lis; Lawrence D. True; Patricia Troncoso; Elizabeth M. Genega; Steven P. Balk; Elahe A. Mostaghel; Trevor M. Penning; Peter S. Nelson; Wanling Xie; Christopher M. Haqq; NamPhuong Tran; Weimin Peng; Daniel Tamae; Thian Kheoh; Arturo Molina; Philip W. Kantoff; Mary-Ellen Taplin. Effect of Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate on PSA, Pathologic Response, and Intraprostatic/Serum Androgen Levels in Localized High-Risk Prostate Cancer: Results of a Randomized Phase 2 Study. AUA (#665), 2013.
 10. Sankar N. Maity, Guanglin Wu, Jing-fang Lu, Joel R. Eisner, Stephen W. Rafferty, Robert J. Schotzinger, William R. Moore, Christopher J. Logothetis, John C. Araujo, Eleni Efstathiou. Efficacy of VT-464, a novel selective inhibitor of cytochrome P450 17,20-lyase, in castrate-resistant prostate cancer models. AACR (#4772), 2013.
 11. Xinhai Wan, Paul Corn, Jun Yang, Eleni Efstathiou, Elsa M. Li Ning Tapia, Fen Wang, Wallace McKeehan, Christopher Logothetis, Patricia Troncoso, Nora M. Navone. Fibroblast growth factor receptor blockade in prostate cancer bone metastases. AACR (#2436), 2013.
 12. Dana E. Rathkopf, Matthew R. Smith, Johann Sebastian De Bono, Christopher Logothetis, Neal Shore, Paul L. De Souza, Karim Fizazi, Peter Mulders, Paul N. Mainwaring, John D Hainsworth, Tomasz M. Beer, Scott A. North, Yves Fradet, Thomas W. Griffin, Youn Choi

- Park, Thian San Kheoh, Eric Jay Small, Howard I. Scher, Arturo Molina, Charles J. Ryan; Memorial Sloan-Kettering Cancer Center, New York, NY; Massachusetts General Hospital Cancer Center, Boston, MA; The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; The University of Texas MD Anderson Cancer Center, Houston, TX; Carolina Urologic Research Center, Myrtle Beach, SC; University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia; Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Radboud University Medical Centre, Nijmegen, Netherlands; Haematology and Oncology Clinics of Australia, Brisbane, Australia; Sarah Cannon Research Institute, Nashville, TN; Oregon Health & Science University Knight Cancer Institute, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Laval University, Québec, QC, Canada; Janssen Research & Development, LLC, Los Angeles, CA; Janssen Research & Development, LLC, Raritan, NJ; Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302). ASCO (#5009), 2013.
13. Brittany N. Kleb, Marcos RH Estecio, Guanglin Wu, Jing-Fang Lu, Christopher J. Logothetis, Sankar Maity, Ana M. Aparicio. Mechanism of androgen receptor (AR) silencing in small cell prostate carcinoma. AACR (#2986), 2013.
 14. Paul G. Corn, Andreas Varkaris, Elsa M. Li Ning Tapia, John C. Araujo, Ana Aparicio, Shi-Ming Tu, Amado J. Zurita, Eleni Efstathiou, Wei Qiao, Sijin Wen, Gary E. Gallick, Christopher Logothetis; The University of Texas MD Anderson Cancer Center, Houston, TX; West Virginia University Health Science Center, Morgantown, WV. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. Genitourinary Cancers Symposium (#58), 2013.
 15. John C. Araujo, Geralyn C. Trudel, Fred Saad, Andrew J. Armstrong, Evan Y. Yu, Joaquim Bellmunt, George Wilding, John McCaffrey, Sergio V. Serrano, Vsevolod Matveev, Eleni Efstathiou, Stephane Oudard, Michael J. Morris, Bruce Sizer, Peter J. Goebell, Johann Sebastian De Bono, Prashni Paliwal, Susan Durham, Shinta Cheng, Christopher Logothetis; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; Bristol-Myers Squibb, Montreal, QC, Canada; Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada; Duke Cancer Institute and the Duke Prostate Center, Division of Medical Oncology and Urology, Duke University, Durham, NC; University of Washington and Seattle Cancer Care Alliance, Seattle, WA; University Hospital del Mar-IMIM, Barcelona, Spain; University of Wisconsin Carbone Cancer Center, Madison, WI; Irish Clinical Oncology Research Group (ICORG), Dublin, Ireland; Hospital de Cancer de Barretos, Sao Paulo, Brazil; N.N. Blokhin Cancer Research Center, Moscow, Russia; Department of Clinical Therapeutics, The University of Athens, Athens, Greece; Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France; Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Essex County Hospital, Colchester, United Kingdom; Department of Urology, Friedrich-Alexander-Universitaet, Erlangen, Germany; Institute of Cancer Research/Royal Marsden Hospital, Sutton, United Kingdom; Bristol-Myers Squibb, Wallingford, CT; Bristol-Myers Squibb, Princeton, NJ. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. Genitourinary Cancers Symposium (#LBA8), 2013.
 16. Mehmet Asim Bilen, Sue-Hwa Lin, Rosale General, Lance C. Pagliaro, Christopher Logothetis, Ivan Gorlov, Shi-Ming Tu; Baylor College of Medicine, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX. Prediction of a potential lethal phenotype in testicular nonseminomatous germ cell tumor. ASCO (#e15575), 2013.
 17. Charles J. Ryan, Anil Londhe, Arturo Molina, Matthew R. Smith, Johann Sebastian De Bono, Peter Mulders, Dana E. Rathkopf, Fred Saad, Christopher Logothetis, Karim Fizazi, Howard I. Scher, Eric Jay Small, Shannon Matheny, Thian San Kheoh, Thomas W. Griffin; Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA; Janssen Research & Development, LLC, Raritan, NJ; Janssen Research & Development, LLC, Los Angeles, CA; Massachusetts General Hospital Cancer Center,

- Boston, MA; The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Radboud University Medical Centre, Nijmegen, Netherlands; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Montreal, Montreal, QC, Canada; The University of Texas MD Anderson Cancer Center, Houston, TX; Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. ASCO (#5010), 2013.
18. Jeri Kim, John Francis Ward, Curtis A. Pettaway, Xuemei Wang, Deborah A. Kuban, Steven J. Frank, Andrew Lee, Louis L. Pisters, Surena F. Matin, Jay Bakul Shah, Jose A. Karam, Brian Francis Chapin, John N. Papadopoulos, Mary F. Achim, Karen Elizabeth Hoffman, Thomas J. Pugh, Seungtaek Choi, Christopher Logothetis, Patricia Troncoso, John W. Davis; The University of Texas MD Anderson Cancer Center, Houston, TX. Risk of missing advanced stage or high grade tumors during active surveillance (AS) even in favorable-risk prostate cancer (PC). ASCO (#5069), 2013.
 19. Farshid Dayyani, Graciela M. Noguerras-Gonzalez, Rebecca Slack, Randall E. Millikan, Amado J. Zurita, John C. Araujo, Gary E. Gallick, Christopher Logothetis, Paul Gettys Corn; The University of Texas MD Anderson Cancer Center, Houston, TX; Essentia Health Cancer Center (Duluth), Duluth, MN. Serum insulin to predict time to castration-resistant progression and overall survival in metastatic androgen-dependent prostate cancer (mADPCa). ASCO (#e16038), 2013.
 20. Farshid Dayyani, Andreas Varkaris, John C. Araujo, Jian H. Song, Geralyn C. Trudel, Christopher Logothetis, Gary E. Gallick; The University of Texas MD Anderson Cancer Center, Houston, TX; Bristol-Myers Squibb, Montreal, QC, Canada. Serum insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer. Genitourinary Cancers Symposium (#166), 2013.
 21. Neal Shore; Ethan Basch; Charles J. Ryan; Peter Mulders; Thian Kheoh; Karim Fizazi; Christopher J. Logothetis; Dana Rathkopf; Matthew R. Smith; Paul N. Mainwaring; Yanni Hao; Thomas Griffin; Susan Li; Michael L. Meyers; Arturo Molina; Charles Cleeland. The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-naïve patients with progressive, metastatic castration-resistant prostate cancer – results from an updated analysis. AUA (#784), 2013.
 22. Dana E. Rathkopf, Matthew Raymond Smith, Johann Sebastian De Bono, Christopher Logothetis, Neal D. Shore, Paul L. De Souza, Karim Fizazi, Peter Mulders, Paul N. Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott A. North, Yves Fradet, Thomas W. Griffin, Youn Choi Park, Thian San Kheoh, Eric Jay Small, Howard I. Scher, Arturo Molina, Charles J. Ryan; Memorial Sloan-Kettering Cancer Center, New York, NY; Massachusetts General Hospital Cancer Center, Boston, MA; Institute of Cancer Research/Royal Marsden Hospital, Sutton, United Kingdom; The University of Texas MD Anderson Cancer Center, Houston, TX; Carolina Urologic Research Center, Myrtle Beach, SC; University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia; Institut Gustave Roussy, Villejuif, France; Radboud University Medical Centre, Nijmegen, Netherlands; Haematology and Oncology Clinics of Australasia, Brisbane, Australia; Sarah Cannon Research Institute, Nashville, TN; Oregon Health and Science University, Knight Cancer Institute, Portland, OR; Cross Cancer Institute, Edmonton, AB, Canada; Laval University, Québec, QC, Canada; Janssen Research & Development, Los Angeles, CA; Janssen Research & Development, Raritan, NJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; University of California, San Francisco, San Francisco, CA. Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. Genitourinary Cancers Symposium (#05), 2013.
 23. Nallasivam Palanisamy, Jun Yang, Xinhai Wan, John C. Araujo, Eleni Efstathiou, Louis Pisters, Ritu Bhalla, Scott Tomlins, Lakshmi P. Kunju, Arul Chinnaiyan, Christopher J. Logothetis, Patricia Troncoso, Nora M. Navone. Xenografts of human prostate cancer - a genetic profile analysis. AACR (#2780), 2013.

24. Christopher Logothetis, Gary E. Gallick, Sue-Hwa Lin, and Nora Navone. The role of bone microenvironment in the lethal progression of prostate cancer. AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment (#IA11), 2/2014.
25. Efsthathiou E, Li Ning Tapia E, Aparicio A, Tu SM, Wen S, Hoang A, Pagliaro L, Harmon C, Troncoso P, Araujo JC, Logothetis C. Maximal Androgen Depletion with Abiraterone Acetate (AA) Followed By Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies Dasatinib or Sunitinib Malate in Metastatic Castrate Resistant Prostate Cancer (MCRPC). Report on Candidate Predictive Androgen Signaling Signature. ESMO (#LBA21), 9/2014.
26. Fizazi K, Drake CJ, Kwon ED, Bossi A, van den Eertwegh AJ, Scher HI, Beer TM, McHenry MB, Liu D, Gerritsen WR, Logothetis C. Updated Overall Survival (OS) From the Phase 3 Trial, CA184-043: Ipilimumab (IPI) vs Placebo (PBO) in Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (MCRPC). ESMO (#763PD), 9/2014.
27. Jian Gu, Yonggang He, Sara S. Strom, Christopher J. Logothetis, Jeri Kim, Xifeng Wu. A genetic variant near KLK3 gene is associated with aggressive prostate cancer and can stratify Gleason score 7 patients. AACR (#5547), 2014.
28. Eleonora Dondossola, Stephanie Alexander, Steve Alexander, Boris M. Holzapfel, Christopher J. Logothetis, Dietmar W. Hutmacher, Peter Fried. A humanized bone model for preclinical monitoring of prostate cancer lesions by intravital multiphoton microscopy. AACR (#4941), 2014.
29. Paul Gettys Corn, Shi-Ming Tu, Amado J. Zurita, John C. Araujo, Lance C. Pagliaro, Christopher Logothetis, Ana Aparicio. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. Genitourinary Cancers Symposium (#148), 2014.
30. John W. Davis, Mary F. Achim, John Francis Ward, Curtis Alvin Pettaway, Brian Francis Chapin, Xuemei Wang, Deborah A. Kuban, Steven J. Frank, Andrew Lee, Louis L. Pisters, Surena F. Matin, Jay Bakul Shah, Jose A. Karam, John N. Papadopoulos, Karen Elizabeth Hoffman, Thomas J. Pugh, Seungtaek Choi, Christopher Logothetis, Patricia Troncoso, Jeri Kim. Active surveillance in phenotypically heterogeneous early-stage prostate cancer. ASCO (#5083), 2014.
31. Evan Y. Yu, Fred Saad, Anil Londhe, Neal D. Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Christopher Logothetis, Paul L. De Souza, Karim Fizazi, Peter F.A. Mulders, Paul N. Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott A. North, Eric Jay Small, Howard I. Scher, Thomas W. Griffin, Margaret K. Yu, Charles J. Ryan. Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. Genitourinary Cancers Symposium (#27), 2014.
32. Patricia A. Parker, John W. Davis, David Latini, George Baum, Xuemei Wang, John Francis Ward, Deborah A. Kuban, Steven J. Frank, Andrew Lee, Christopher Logothetis, Jeri Kim. Associations between uncertainty, anxiety, and quality of life in men with favorable-risk prostate cancer on active surveillance: Two-and-a-half years' follow-up. Genitourinary Cancers Symposium (#135), 2014.
33. Tomasz M. Beer, Christopher Logothetis, Winald R. Gerritsen, Eugene D. Kwon, Howard I. Scher, Alberto Bossi, Alfons JM van den Eertwegh, Charles G. Drake, Brent McHenry, David Liu, Karim Fizazi. Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC. Genitourinary Cancers Symposium (#52), 2014.
34. Shore, Neal (Myrtle Beach, SC); Rathkopf, Dana; Smith, Matthew R.; de Bono, Johann S.; Logothetis, Christopher; de Souza, Paul; Fizazi, Karim; Mulders, Peter F.A.; Mainwaring, Paul; Hainsworth, John D.; Beer, Tomasz M.; North, Scott; Fradet, Yves; Griffin, Thomas; Park, Youn C.; Kheoh, Thian; Small, Eric J.; Scher, Howard I.; Molina, Arturo; Ryan, Charles J. Efficacy and Long-term Safety Analysis of Study COU-AA-302: Abiraterone Acetate Plus Prednisone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. AUA (#PD27-01), 2014.

35. Eleni Efstathiou, Mark Anton Titus, Sijin Wen, Aileen SanMiguel, Anh Hoang, Angela De Haas-Amatsaleh, Frank Perabo, De Phung, Patricia Troncoso, Taoufik Ouatas, Christopher Logothetis. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). ASCO (#5000), 2014.
36. Subudhi SK, Aparicio A, Zurita AJ, Araujo JC, Corn PG, Tu SM, Wang X, Harris DR, Winslow KA, Gao J, Logothetis CJ, Sharma P. Finite androgen deprivation therapy (ADT) plus ipilimumab (IPI) in men with hormon-naive metastatic prostate cancer (HN-MPCa). ESMO (#7175), 2014.
37. Zurita AJ, Carlsson A, Luttgen MS, Bethel K, Logothetis CJ, Hicks J, Kuhn P, . High-Definition Single Cell Analysis (HD-SCA) of Prostate Cancer (PCa) Cells in Matched Bone Marrow and Blood from Patients. ESMO (#7223), 2014.
38. Shi-Ming Tu, Mehmet Asim Bilen, Zachary H. Tu, Raphael General, John Francis Ward, Louis L. Pisters, Rosale General, Adrienne H. Chen, Yago Nieto, Lance C. Pagliaro, S. J. Yeung, Christopher Logothetis, Sue-Hwa Lin, Ivan Gorlov. Nonseminomatous germ cell tumor of the testis: Prognostic factors for a lethal phenotype. Genitourinary Cancers Symposium (#390), 2014.
39. Yohann Lorient, Lance C. Pagliaro, Aude Flechon, Jozef Mardiak, Lionnel Geoffrois, Pierre Kerbrat, Christine Chevreau, Remy Delva, Frederic Rolland, Christine Theodore, Binh Bui, Gwenaelle Gravis, Jean-Christophe Eymard, Jean-pierre Malhaire, Claude Linassier, Muriel Habibian, Christopher Logothetis, Stephane Culine, Agnes Laplanche, Karim Fizazi. Patterns of relapse in poor-prognosis germ cell tumors in the GETUG 13 trial: Implications for assessment of brain progression. Genitourinary Cancers Symposium (#365), 2014.
40. Sankar Narayan Maity, Guanglin Wu, Jing-Fang Lu, Anh Hoang, Yosef Landesman, Dilara McCauley, Sharon Shacham, Michael G. Kauffman, Ana M. Aparicio, Eleni Efstathiou, John C. Araujo, Christopher J. Logothetis. Preclinical efficacy of the novel, oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) on castration resistant prostate cancer. AACR (#3808), 2014.
41. Deborah Sokol Ricci, Weimin Li, Thomas W. Griffin, Michael Gormley, Erin Henitz, Charles J. Ryan, Johann Sebastian De Bono, Gerhardt Attard, Alfons JM van den Eertwegh, Dirk L. Schrijvers, John J. Gullo, Henrik Suttman, Joan Carles, Jose Maria Piulats Rodriguez, Robert J. Jones, Christopher Logothetis, Dana E. Rathkopf, Howard I. Scher, Eleni Efstathiou. Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302. ASCO (#5058), 2014.
42. Charles G. Drake, Eugene D. Kwon, Karim Fizazi, Alberto Bossi, Alfons JM van den Eertwegh, Christopher Logothetis, Howard I. Scher, Tomasz M. Beer, Brent McHenry, David Liu, Winald R. Gerritsen. Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium (#02), 2014.
43. Mehmet Asim Bilen, Kenneth R. Hess, Ana Aparicio, Jeri Kim, Amado J. Zurita, Lance C. Pagliaro, John C. Araujo, Paul Gettys Corn, Bradley J. Atkinson, Nizar M. Tannir, Padmanee Sharma, Sue-Hwa Lin, Christopher Logothetis, Shi-Ming Tu. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). ASCO (#e16046), 2014.
44. William R. Moore, Sankar N. Maity, Joel Robert Eisner, Edward P. Garvey, William J. Hoekstra, Mark Anton Titus, Christopher Logothetis, John C. Araujo, Eleni Efstathiou, Robert J. Schotzinger. The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models. Genitourinary Cancers Symposium (#158), 2014.
45. Ana Aparicio, Li Shen, Elsa Li Ning Tapia, Jing-Fang Lu, Hsiang-Chun Chen, Jiexin Zhang, Guanglin Wu, Xuemei Wang, Patricia Troncoso, Bradley McIntosh Broom, Keith A. Baggerly, Christopher Logothetis, Sankar N. Maity. A comprehensive molecular characterization of aggressive variant prostate cancer (PC). Genitourinary Cancers Symposium (#149), 2/2015.
46. Sankar N. Maity, Guanglin Wu, Jing-Fang Lu, Anh Hoang, Yosef Landesman, Dilara McCauley, Robert Carlson, Tami Rashal, Sharon Shacham, Bradley McIntosh Broom, Keith A. Baggerly, Ana Aparicio, Eleni Efstathiou, John C. Araujo, Christopher Logothetis. Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor

- suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth. *Genitourinary Cancers Symposium (#277)*, 2/2015.
47. Rozita Bagheri-Yarmand, Sharmistha Lahiri, Xinhai Wan, Nora Navone, Christopher J. Logothetis, Robert F. Gagel, and Krishna M. Sinha. A novel epigenetic regulator histone demethylase NO66 promotes prostate cancer bone metastasis. *AACR (#2272)*, 4/2015.
 48. Estefania Labanca, Xinhai Wan, Jun Yang, Matthew Iyer, Christopher Logothetis, Arul Chinnaiyan, and Nora Navone. Fibroblast growth factor receptor 1 isoforms in prostate cancer bone metastases. *AACR (#3913)*, 4/2015.
 49. Eleonora Dondossola, Stephanie Alexander, Steve Alexander, Boris Holzapfel, Christopher Logothetis, Dietmar Huttmacher, and Peter Friedl. Preclinical monitoring of prostate cancer lesions in bone by intravital multiphoton microscopy. *AACR (#5175)*, 4/2015.
 50. Paul Gettys Corn, Shi-Ming Tu, Amado J. Zurita, Sumit Kumar Subudhi, John C. Araujo, Jeri Kim, Eric Jonasch, Lance C. Pagliaro, Arlene O. Siefker-Radtke, Jennifer Wang, Xuemei Wang, Elisabeth I. Heath, Christopher Logothetis, Ana Aparicio. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). *ASCO (#5010)*, 5/2015.
 51. Brian Francis Chapin, Sean Eric Mcguire, Xuemei Wang, Patricia Troncoso, John W. Davis, Neema Navai, Sumit Kumar Subudhi, Amado J. Zurita, John C. Araujo, Curtis Alvin Pettaway, Surena F. Matin, Louis L. Pisters, John Francis Ward, Shi-Ming Tu, Jennifer Wang, Ott Le, Christopher Logothetis, Ana Aparicio. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer. *ASCO (#TPS5075)*, 5/2015.
 52. Eleni Efstathiou, Weimin Li, Michael Gormley, Ryan McMullin, Deborah Sokol Ricci, John W. Davis, Elsa M. Li Ning Tapia, Patricia Troncoso, Mark Anton Titus, Anh Hoang, Sijin Wen, Amado J. Zurita, Namphuong Tran, Weimin Peng, Thian Kheoh, Arturo Molina, Christopher Logothetis. Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. *ASCO (#5005)*, 5/2015.
 53. Eleni Efstathiou, Patricia Troncoso, Elsa Li Ning Tapia, John W. Davis, Mark Anton Titus, Anh Hoang, Ina N. Prokhorova, Sijin Wen, Christopher Logothetis. Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk prostate cancer (LHRPC). *ASCO (#5061)*, 5/2015.
 54. Ana Aparicio, Li Shen, Elsa Li Ning Tapia, Jing-Fang Lu, Hsiang-Chun Chen, Jiexin Zhang, Guanglin Wu, Xuemei Wang, Patricia Troncoso, Paul Gettys Corn, Timothy C. Thompson, Bradley McIntosh Broom, Keith A. Baggerly, Christopher Logothetis, Sankar N. Maity. Molecular characterization of clinically defined aggressive variant prostate cancer (AVPCa) in prospectively collected tissues and corresponding patient derived xenografts (PDX). *ASCO (#5055)*, 5/2015.
 55. Charles J. Ryan, Matthew Raymond Smith, Karim Fizazi, Fred Saad, Cora N. Sternberg, Christopher Logothetis, Eric Jay Small, Joan Carles, Thomas W. Flaig, Mary-Ellen Taplin, Celestia S. Higano, Paul L. De Souza, Johann Sebastian De Bono, Thomas W. Griffin, Peter De Porre, Youn Choi Park, Jinhui Li, Thian San Kheoh, Arturo Molina, Dana E. Rathkopf. Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis. *Genitourinary Cancers Symposium (#142)*, 2015.
 56. Amado J. Zurita, Anders Carlsson, Madelyn S. Luttgen, Kelly Bethel, Patricia Troncoso, Paul Gettys Corn, Anand Kolatkar, James B Hicks, Christopher Logothetis, Peter Kuhn. A clinically applicable strategy to concurrently profile prostate cancer (PCa) in circulation and bone using high-definition single cell analysis (HD-SCA). *ASCO (#5041)*, 6/2016.
 57. Sumit Kumar Subudhi, Ana Aparicio, Patricia Troncoso, Jianhua Zhang, Curtis Gumbs, Chang-jiun Wu, Luis M Vence, Christopher Logothetis, Andrew Futreal, James Patrick Allison, Padmanee Sharma. A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). *ASCO (#e14506)*, 6/2016.

58. Paul Gettys Corn, Elsa Li Ning Tapia, Lianchun Xiao, Elisabeth I. Heath, Haidee Chancoco, Anh Hoang, Eleni Efstathiou, Timothy C. Thompson, Patricia Troncoso, Christopher Logothetis, Ana Aparicio. Confirmatory analysis to determine associations between platinum-sensitivity, molecular signature of combined tumor suppressor defects and aggressive variant prostate carcinomas (AVPC). ASCO (#5020), 6/2016.
59. Karim Fizazi, Aude Flechon, Gwenael / Le Teuff, Jozef Mardiak, Lance C. Pagliaro, Lionel Geoffrois, Pierre Kerbrat, Christine Chevreau, Remy Delva, Frederic Rolland, Christine Theodore, Guilhem Roubaud, Gwenaelle Gravis, Jean-Christophe Eymard, Jean-pierre Malhaire, Claude Linassier, Muriel Habibian, Maria Reckova, Christopher Logothetis, Stephane Culine. Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT). ASCO (#4504), 6/2016.
60. Eleni Efstathiou, John W. Davis, Mark Anton Titus, Brian Francis Chapin, Amado J. Zurita, Sijin Wen, Elsa M. Li Ning Tapia, Anh Hoang, Paul Gettys Corn, Xuemei Wang, Francine Whittington, Patricia Troncoso, Christopher Logothetis. Neoadjuvant enzalutamide (ENZA) and abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus AA+ LHRHa in localized high-risk prostate cancer (LHRPC). ASCO (#5002), 6/2016.
61. Spyridon P Basourakos, John W. Davis, Brian Francis Chapin, John Francis Ward, Curtis Alvin Pettaway, Louis L. Pisters, Mary F. Achim, Xuemei Wang, Seungtaek Choi, Deborah A. Kuban, Patricia Troncoso, Christopher Logothetis, Timothy C. Thompson, Jeri Kim. Plasma caveolin-1 to predict disease reclassification in men with early stage prostate cancer in active surveillance. ASCO (#5052), 6/2016.
62. Efstathiou E, Tsikkinis A, Wen S, Li Ning Tapia E, Hoang A, Aparicio A, Tu S-M, Rangel G, Troncoso P, Corn P, Araujo J, Logothetis C. Abiraterone acetate (AA) followed by randomization to dasatinib (D) or sunitinib malate (S) in metastatic castrate resistant prostate cancer (mCRPC). ESMO (#727PD), 10/2016.
63. Paul Gettys Corn, Amado J. Zurita, Sumit Kumar Subudhi, Shi-Ming Tu, Ana Aparicio, John C. Araujo, Jeri Kim, Jennifer Wang, Eleni Efstathiou, Lance C. Pagliaro, Christopher Logothetis. Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer. Genitourinary Cancers Symposium (#169), 2/2017.
64. Jianjun Gao, John Francis Ward, Curtis Alvin Pettaway, Lewis Z Shi, Sumit Kumar Subudhi, Luis M Vence, Hao Zhao, Jianfeng Chen, Hong Chen, Eleni Efstathiou, Patricia Troncoso, James Patrick Allison, Christopher Logothetis, Ignacio Ivan Wistuba, Jennifer Ann Wargo, Jorge M Blando, Manuel A Sepulveda, Jing Jing Sun, Padmanee Sharma. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. ASCO (#5081), 6/2017.
65. Sumit Kumar Subudhi, Ana Aparicio, Patricia Troncoso, Jianhua Zhang, Curtis Gumbs, Chang-jiun Wu, Jianjun Gao, Luis M Vence, Jorge M Blando, Paul Gettys Corn, John C. Araujo, Amado J. Zurita, Ina N. Prokhorova, Michael Van Alstine, Christopher Logothetis, Andrew Futreal, James Patrick Allison, Padmanee Sharma. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). ASCO (#5065), 6/2017.
66. Celestia S. Higano, Shawn H. Zimberg, Sabina Dizdarevic, Lauren Christine Harshman, John Logue, Sergio Baldari, Timothy Richardson, David M. Bottomley, Martin Schostak, Bertrand F. Tombal, Juan Pablo Sade, Kurt Miller, Christopher Logothetis, Joaquim Bellmunt, Matthew Raymond Smith, Fred Saad, Renate Muenz-Wollny, Yoriko De Sanctis, A. Oliver Sartor, Cora N. Sternberg. Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study. ASCO (#5042), 6/2017.
67. Ana Aparicio, Lianchun Xiao, Elsa Li Ning Tapia, Anh Hoang, Naveen Ramesh, Wenhui Wu, Haidee Chancoco, Elisabeth I. Heath, Eleni Efstathiou, Timothy C. Thompson, Patricia Troncoso, Bradley McIntosh Broom, Amado J. Zurita, Nicholas Navin, Christopher Logothetis, Paul Gettys Corn. The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC). ASCO (#5013), 6/2017.

Book Chapters

1. Logothetis, CJ, von Eschenbach AC, Samuels ML, Trindade A, Johnson DE. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: A preliminary report. In: Year Book of Cancer, 134-136, 1983.
2. Logothetis CJ. Perioperative chemotherapy for the management of primary local regional urothelial tumors. In: Primary Chemotherapy in Cancer Medicine. 201. Alan R. Liss, Inc., 359-366, 1985.
3. Logothetis CJ. Preoperative chemotherapy in the treatment of germinal tumors. In: Primary Chemotherapy in Cancer Medicine. 201. Alan R. Liss, Inc., 341-350, 1985.
4. Logothetis CJ. Extragonadal germ cell tumors. In: Principles and Management of Testicular Cancer. Thieme Inc., 355-350, 1986.
5. Johnson, DE, Logothetis CJ, Zagars GK, Smith DB. Special problems posed by cancer treatments. In: Ostomy Care and the Cancer Patient. Surgical and Clinical Considerations. 8. Grune and Stratton, Inc., 121-131, 1986.
6. Logothetis, CJ, Johnson DE, Chong C, Dexeus FH, Ogden S, von Eschenbach AC, Ayala AG. Adjuvant CISCA for patients with high risk bladder cancer. In: Adjuvant Therapy of Cancer V.. Grune and Stratton, Inc., 565-570, 1987.
7. Swanson DA, Logothetis CJ. Metastatic transitional cell carcinoma. In: Current Therapy in Genitourinary Surgery.. B. C. Decker Inc., 69-73, 1987.
8. Logothetis CJ. Testicular cancer and other tumors of the male genitourinary tract. In: Cancer Chemotherapy by Infusion. 27. Precept Press Inc., 353-367, 1987.
9. Logothetis CJ. Testicular cancer. In: Cancer Update 87: Committee of Medical Oncology Fellows Board Review, M. D. Anderson Hospital and Tumor Institute., 1987.
10. Logothetis CJ. Vinblastine and bleomycin combination in the management of germ cell tumors (Part I); Prostatic carcinoma (Part II); Urothelial tumors (Part III). In: Cancer Chemotherapy by Infusion. 27. Precept Press Inc., 353-367, 1987.
11. Logothetis, CJ, Chong C, Dexeus FH, Sella A, Ogden S. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors. In: Uro-Oncology: Current Status and Future Trends. Alan R. Liss, Inc., 301-307, 1988.
12. Swanson DA, Logothetis CJ. Primary chemotherapy for clinical stage II nonseminomatous testicular carcinoma. In: Advances in Urology. Year Book Medical Publishers, Inc., 129-144, 1988.
13. Dexeus, FH, Logothetis CJ, Sipahi H. Chemotherapy for advanced squamous carcinoma of the male external genital tract and urethra. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 255-259, 1989.
14. Chong C, Logothetis CJ. Chemotherapy for extragonadal germ cell tumors: The M. D. Anderson experience. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 363-369, 1989.
15. Logothetis CJ. CISCA chemotherapy for disseminated bladder carcinoma. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 43-47, 1989.
16. Chong CDK, Logothetis CJ. Cisplatin-based chemotherapy for metastatic pure seminoma. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers., 280-285, 1989.
17. Logothetis, CJ, Dexeus F, Chong C, Sella A, Finn L. Cytotoxic chemotherapy for hormone-refractory metastatic prostate cancer. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 234-238, 1989.
18. Logothetis CJ, Ro JY. Germ cell tumors: Clinically relevant advances. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 272-279, 1989.
19. Logothetis, CJ, Johnson DE, von Eschenbach A. Germ cell tumors: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 380-384, 1989.
20. Logothetis, CJ, Chong CDK, Ogden S. Long term follow-up of patients treated with cyclic CISCA/IVBIV at the University of Texas M. D. Anderson Cancer Center. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 349-355, 1989.
21. Sella, A, Logothetis CJ, Dexeus FH, Amato RJ, Ogden S. Long-term cure rate in 154 testicular nonseminomatous germ cell tumor (NSGCTT) patients treated with aggressive chemotherapy. In: Proceedings of the 16th International Congress of Chemotherapy. June, 1989.

22. Logothetis CJ. Postoperative adjuvant CISCA chemotherapy for high risk invasive bladder cancer. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 73-76, 1989.
23. Logothetis, CJ, Swanson D, Ogden S. Primary chemotherapy for retroperitoneal nodal disease (clinical stage II). In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 326-330, 1989.
24. von Eschenbach, AC, Johnson DE, Logothetis CJ. Prostate cancer: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers., 251-254, 1989.
25. Johnson, DE, von Eschenbach A, Logothetis CJ. Renal cell carcinoma: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers., 140-142, 1989.
26. Chong C, Logothetis CJ. Treatment of advanced transitional cell carcinoma of the renal pelvis and ureter. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 94-100, 1989.
27. Johnson, DE, Logothetis CJ, von Eschenbach A. Urinary tract tumors: Commentary. In: Systemic Therapy for Genitourinary Cancers. Year Book Medical Publishers, 101-104, 1989.
28. Logothetis, CJ, Chong CD-K, Dexeus FH, Sella A, Ogden S. Intensive chemotherapy for metastatic nonseminomatous germ cell tumors. In: Uro-Oncology: Current Status and Future Trends. Alan R. Liss, Inc., 301-307, 1990.
29. Wallace, S, Charnsangavej C, Carrasco CH, Logothetis CJ. Intra-arterial chemotherapy of genitourinary tumors. In: Clinical Urography. W. B. Saunders Company, 3018-3026, 1990.
30. Logothetis, CJ, Dexeus FH, Chong CD-K, Sella A, Ogden S. The impact of chemotherapy on the survival of patients with metastatic urothelial tumors. In: Uro-Oncology: Current Status and Future Trends. Alan R. Liss, Inc., 107-114, 1990.
31. Kilbourn, RG, Owen-Schaub L, Griffith OW, Logothetis CJ. IL-2 mediated hypotension in the awake dog is reversed by inhibitors of nitric oxide formation. In: Second International Meeting - Biology of Nitric Oxide. Portland Press Ltd., 1991.
32. Sella, A, Amato RJ, Fitz K, Kilbourn RG, Logothetis CJ. Interferon-alpha and 5-fluorouracil combination chemotherapy for metastatic renal cell cancer. In: Interferons and Cytokines. 1, 17-21, 1992.
33. Dexeus F, Logothetis CJ. Penile carcinoma. In: Handbook of Chemotherapy in Clinical Oncology (2nd Edition). Scientific Communication International Ltd., 565-567, 1993.
34. Preti HA, Logothetis CJ. Testicular Cancer. In: Medical Oncology: A Comprehensive Review. PRR, Inc., 295-311, 1993.
35. Logothetis CJ. The management of androgen-independent prostatic carcinoma. In: Prostate Diseases. W. B. Saunders Co, 364-3676, 1993.
36. Sella, A, Finn L, Amato R, Ellerhorst J, Zukiwski A, Kilbourn R, Logothetis CJ. Interferon-(IFN-) Combined with 5-Fluorouracil (5-FU) is an Active Regimen in Metastatic Renal Cell Cancer (RCC). In: Cancer Treatment: An Update. 9891. Springer-Verlag, 535-539, 1994.
37. Amato, R, Finn L, Striegel A, Sella A, Ellerhorst J, Zukiwski A, Logothetis CJ. Salvage therapy in metastatic non-seminomatous germ cell tumour at the University of Texas M. D. Anderson Cancer Center. In: Germ Cell Tumours III, 271-272, 1994.
38. Amato RJ, Logothetis CJ. Chemotherapy for stage I and II testicular cancer. In: Comprehensive Textbook of Genitourinary Oncology. Williams and Wilkins, 1022-1027, 1996.
39. Logothetis, CJ, Hoosein NM, Ro JY. Neuroendocrine progression of prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology. Williams and Wilkins, 914-919, 1996.
40. Denis L, Logothetis CJ. Urothelial cancer: The role of haematopoietic growth factors. In: Consultant Series - Urothelial Cancer. Gardiner-Caldwell Biotech, 1996.
41. Scher HI, Logothetis CJ. Management of androgen-independent prostatic cancer. In: Principles and Practices of Genitourinary Oncology. Lippincott-Raven, 599-612, 1997.
42. Logothetis CJ. Urological complications of malignancies and cancer therapy. In: Cancer Medicine 4th Edition. 2. Williams and Wilkins, 3191-3196, 1997.
43. Hossan Eand Logothetis CJ. Chapter 10 - Management of hormone refractory disease. In: International Handbook of Prostate Cancer, 137-148, 1999.

44. Logothetis CJ, Vogelzang NJ. Chapter 46B-Current Treatment and Investigative Approaches to the Management of Hormone-Refractory Prostate Cancer. In: *Comprehensive Textbook of Genitourinary Oncology*, 862-869, 1999.
45. Logothetis CJ, Moon C. Chapter 225-Endocrine Aspects of Prostate Cancer. In: *Principles and Practice of Endocrinology and Metabolism*, 2000.
46. Logothetis CJ, Assikis V, Sarriera JE. Urologic Complications. In: *Holland-Frei Cancer Medicine 6th Edition*. BC Decker Inc, 2003.
47. Efstathiou E, Logothetis CJ. Clinical Challenges for Treatment and a Cure. In: *The Biology and Treatment of Cancer*. John Wiley & Sons, Inc., 155-67, 2008. PMID: 9780470374252.
48. Logothetis CJ. Strategy for the application of therapy in prostate cancer. In: *Adv Exp Med Biol*. 617, 193-9, 2008. PMID: 18497043.
49. Corn P, Logothetis CJ. Chapter 34: Prostate Cancer. In: *The MD Anderson Manual of Medical Oncology, 2e*. The McGraw-Hill Companies, 2011.
50. Bilen MA, Logothetis CJ, Corn PG. Chapter 37: Prostate Cancer. In: *The MD Anderson Manual of Medical Oncology, Third Edition, Third*. Ed(s) Kantarjian HM, Wolff RA. McGraw-Hill Education, 773-791, 2016.
51. Logothetis CJ, Kim J, Davis JW, Chapin BF, Kuban D, Efstathiou E, Aparicio A. Neoplasms of the prostate. In: *Holland-Frei Cancer Medicine 9th Edition, Ninth*. Wiley-Blackwell, 1205-1235, 2017.
52. Sanford RA, Abudayyeh A, Logothetis CJ, Tannir, NM. Urologic complications. In: *Holland-Frei Cancer Medicine 9th Edition, Ninth*. Wiley-Blackwell, 1755-1762, 2017.

Books (edited and written)

N/A

Letters to the Editor

1. Logothetis CJ. Bladder cancer histology reported to influence response to treatment (editorial). *Urology Times* 1:380, 4/1984.
2. Logothetis CJ. Endodermal sinus tumors. *Chest* 88(1):6-7, 7/1985. PMID: 2408823.
3. Logothetis CJ, Samuels ML. Prognostic factors in disseminated germ cell tumors. *J Clin Oncol* 4(8):1278-80, 8/1986. PMID: 3016207.
4. Logothetis CJ. Lhermittes sign following cisplatin therapy for a patient with CISCAII/VBIV (editorial). *American Journal of Medicine* 82(3):575-576, 3/1987.
5. Logothetis CJ. Have aggressive chemotherapy regimens improved results in advanced germ cell tumors. *Eur J Cancer Clin Oncol* 23(9):1415-6, 9/1987. PMID: 2445581.
6. Logothetis CJ. Carcinoma-in-situ of the testis. *Lancet* 2(8565):977, 10/1987. PMID: 2889904.
7. Logothetis CJ. Adjuvant chemotherapy for testicular cancer. *N Engl J Med* 319(1):53, 7/1988. PMID: 2837667.
8. Sella A, Logothetis CJ, Dexeus FH, Amato R. Pulmonary air cyst associated with combination chemotherapy containing bleomycin. *AJR Am J Roentgenol* 153(1):191, 7/1989. PMID: 2472057.
9. Logothetis CJ. Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Progress in Clinical and Biological Research. *Journal of the National Cancer Institute* 83(11):786, 6/1991.
10. Logothetis CJ. Organ Preservation in Bladder Carcinoma: A Matter of Selection. *Journal of Clinical Oncology* 9(9):1525-1526, 1991.
11. Logothetis CJ, Amato RJ. Dose intensity in germ cell tumors: lessons learned? *J Natl Cancer Inst* 84(22):1686-7, 11/1992. PMID: 1331481.
12. von Eschenbach AC, Logothetis CJ. Prostate Cancer. *Cancer Bulletin* 45(5):379-380, 9/1993.
13. Tu SM, Lin SH, Logothetis C. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst* 95(15):1174-5; author reply 1175, 8/2003. PMID: 12902452.
14. Pagliaro LC, Tannir NM, Tu SM, Logothetis CJ. Management of Clinical Stage I Testicular Cancer: How Should We Define Success? *J Clin Oncol* 33(20):2321-2, 7/2015. e-Pub 6/2015. PMID: 26033805.

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Editor, Urology Editorial Board, 1997-present

Editor, Urologic Oncology Editorial Board, 1998-present

Associate Editor, Seminars in Urologic Oncology, 2005-present

Editorial Board, Journal of Clinical Oncology, ASCO, 2008-present

Member of Editorial Review Board

N/A

Journal Reviewer

Reviewer, Head and Neck, 1998-present

Reviewer, Journal of Urology, 1998-present

Reviewer, The Gold Journal, 1999-present

Reviewer, Clinical Cancer Research, 2001-present

Reviewer, Urology, 2001-present

Reviewer, Clinical and Experimental Metastasis, 2004-present

Reviewer, Journal of the National Cancer Institute, 2004-present

Reviewer, British Journal of Urology Cancer, 2005-present

Reviewer, Journal of Clinical Oncology, 2005-present

Reviewer, New England Journal of Medicine, 2006-present

Reviewer, Nature Reviews Urology, 2014-present

Reviewer, The Lancet, 2014-present

Reviewer, The Lancet Oncology, 2014-present

Reviewer, Cancer Discovery, 2015-present

Reviewer, European Urology, 2016-present

Other Editorial and Review Activities

N/A

TEACHING

Teaching Within Current Institution -

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

Lecturer, Combination anti-androgen therapy for prostate cancer: clinical trials and tissue analysis, Course Number: MOGR 1501
2/2014

Lecturer, Advances in Prostate Cancer Therapies, Course Number: D112415
10/2014

Lecturer, Transitioning from a Prognostic to a Predictive Model of Therapy Allocation, Course Number: MOCM 1502
3/2015

Lecturer, Flagship 1 - Androgen Signaling Clinical Trials
4/2016

Lecturer, Advances in the Treatment of Prostate Cancer, Course Number: MOCM 1702
6/2016

Lecturer, Prostate Cancer Moon Shot Update, Course Number: MOCM 1702
9/2016

Lecturer, The Biology of Cancer Metastasis: Prostate Function and Metastatic Prostate
Cancer, Course Number: GS041093
Fall 2016, 12/2016

MDA Medical Review Board

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

Supervisor, Jorge Herrada, M.D., 1994-1996

Supervisor, Debra M. Prow, M.D., 1995-1998

Supervisor, Danai Daliani, M.D., 1996-1998

Supervisor, Julie Ellerhorst, M.D., Ph.D., 1996-1998

Supervisor, Arlene Siefker-Radtke, M.D., 1996-2002

Supervisor, Karim Fizazi, M.D., Ph.D., 1997-2000

Supervisor, Vasileios Assikis, M.D., 2002-2003

Supervisor, Paul Mintz, Ph.D., 2002-2005

Supervisor, John Araujo, M.D., Ph.D., 2002-2006

Supervisor, Shifeng Mao, Ph.D., 2002-2008

Supervisor, Elisabeth Plimack, M.D., 2003-2006

Supervisor, Dimitra Tsavachidou, M.D., Ph.D., 2005-2013

Supervisor, Amado Zurita-Saavedra, M.D., 2006-2008

Supervisor, Eleni Efstathiou, M.D., Ph.D., 2006-2008

Supervisor, Maria Karlou, Ph.D., 2008-2011

Clinical Residents and Fellows

Supervisor, Anthony Ruggeri, M.D., 2000

Supervisor, Michael Wang, M.D., 2000

Supervisor, Zhiyong Li, M.D., 2000

Supervisor, Gary Shi, M.D., 2002-2004

Supervisor, James Hou, M.D., 2002-2004

Other Supervisory Teaching

N/A

Teaching Outside Current Institution

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

Lecturer, Overview of Advances in the Treatment Options for Prostate Cancer, Baylor Health Care Systems, Dallas
8/2015

Lecturer, Endocrine and Bone-Targeted Therapy for Prostate Cancer, Research to Practice
11/2015

Lecturer, Transitioning from a Prognostic to a Predictive Classification of Prostate Cancer, Perelman School of Medicine, University of Pennsylvania
11/2015

Lecturer, Approaches to the Treatment of Advanced Prostate Cancer, UCLA
3/2016

Lecturer, Therapy of Renal Cell Carcinoma in the Immunotherapy Era, UCLA
3/2016

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

MD Anderson Cancer Center, The 1st Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 1993

MD Anderson Cancer Center, The 2nd Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 1994

MD Anderson Cancer Center, The 3rd Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 1995

MD Anderson Cancer Center, The 4th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 1996

MD Anderson Cancer Center, The 5th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 1997

MD Anderson Cancer Center, The 6th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 1998

MD Anderson Cancer Center, The 7th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 1999

MD Anderson Cancer Center, The 8th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2000

ASCO, Clinical Problems in Oncology Session, Chicago, IL, Chair, 6/2001

MD Anderson Cancer Center, The 9th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2002

MD Anderson Cancer Center, The 10th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2003

MD Anderson Cancer Center, The 11th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2005

MD Anderson Cancer Center, The 12th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2006

NCI, 13th SPORE Investigators' Workshop, Washington, DC, Chair, 7/2006

MD Anderson Cancer Center, The 13th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2007

MD Anderson Cancer Center, The 14th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2008

MD Anderson Cancer Center, The 15th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2010

MD Anderson Cancer Center, The 16th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2011

MD Anderson Cancer Center, The 17th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2012

MD Anderson Cancer Center, The 18th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2013

MD Anderson Cancer Center, The 19th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2014

The University of Texas MD Anderson Cancer Center, Festschrift: Celebrating the Lifetime Accomplishments of Waun Ki Hong, MD, DMSc, Houston, TX, Session Co-Chair, 8/2014

Sapienza University, 1st Rome International Meeting on Geriatric Oncology, Rome, Italy, Prostate Cancer Session Co-Chair, 12/2014

MD Anderson Cancer Center, The 20th Annual Melvin L Samuels Lectureship, Houston, TX, Chair, 2015

The University of Texas MD Anderson Cancer Center, GAP 2015 Conference, Houston, TX, Genitourinary Cancers Session Co-Chair, 4/2015

MD Anderson Cancer Center, The 21st Annual Melvin L. Samuels Lectureship, Houston, TX, Chair, 1/2017

MD Anderson Cancer Center, Prostate Cancer Moon Shot Symposium, Houston, TX, Chair, 1/2017

Prostate Cancer International Conference, Athens, Greece, Chair, 3/2017

Presentations at National or International Conferences

Invited

Toward a Comprehensive Genomic Analysis of Cancer, NCI/NHGRI Workshop, National Cancer Institute, Bethesda, MD, 7/1/2005

Prostate Cancer, 12th Annual Scientific Retreat, Prostate Cancer Foundation, Scottsdale, AZ, 9/1/2005

Androgen and Chemotherapy of Prostate Cancer, Joint SBUR/ESUR Meeting, Society for Basic Urologic Research, Miami, FL, 12/1/2005

Prostate SPORE, Third Prostate Cancer SPORE Task Force Meeting, NIH/NCI National Biospecimen Network (NBN), Houston, TX, 2/1/2006

Management of Advanced Prostate Cancer, 2006 Annual Meeting, AUA, Atlanta, GA, 5/1/2006

A Strategy for the Application of Therapy in Prostate Cancer, Fifth International Symposium on Hormonal Carcinogenesis, University of Kansas Medical Center, Montpellier, France, 9/9/2006

Prostate Cancer, Symposium: St. Bartholomew's Hospital, St. Bartholomew's Hospital, London, United Kingdom, 10/14/2006

Prostate Cancer, Prostate Cancer Foundation Conference, Prostate Cancer Foundation, Tel Aviv, Israel, 12/9/2007

Intergration of Clinical Observations with Molecular Characterization to Identify Milestones of Lethal Prostate Cancer Progression, AUA Annual Meeting, Urology Care Foundation, San Diego, CA, 5/3/2013

Transitioning from Drug to Therapy Development, 2013 Prouts Neck 2.0 Meeting on Prostate Cancer, Prostate Cancer Foundation, Lake Tahoe, NV, 6/23/2013

Pathology Workshop on t-NEPC, Prostate Cancer Foundation Pathology Workshop on t-NEPC, Prostate Cancer Foundation, New York City, NY, 7/31/2013

Microenvironment as a therapeutic target in prostate cancer, ISCOR 13, Israel Society for Clinical Oncology and Radiation Therapy, Eliat, Israel, 1/14/2014

Prostate cancer - Are we ready to transition from a treatment to curative Paradigm?, ISCOR 13, Israel Society for Clinical Oncology and Radiation Therapy, Eliat, Israel, 1/15/2014

Can Treatment Targeted at the Androgen Signaling Pathway Ever Cure Prostate Cancer?, AACR Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, AACR, San Diego, CA, 1/20/2014

The role of bone microenvironment in the lethal progression of prostate cancer, Cellular Heterogeneity in the Tumor Microenvironment, AACR, San Diego, CA, 2/28/2014

Transitioning from Prognostic to Predictive Modeling of Prostate Cancer, 2014 AUA Annual Meeting, AUA; Urologic Oncology Research Symposium, Orlando, FL, 5/16/2014

Clinical and Molecular Predictors of Survival in Men with CRPC, 2014 AUA Annual Meeting, AUA; SBUR/SUO Joint Session, Orlando, FL, 5/17/2014

Impact of Neoadjuvant/Adjuvant Therapies, 2014 AUA Annual Meeting, AUA; International Prostate Forum, Orlando, FL, 5/18/2014

The Future of CRPC Sequencing and Combinations, 2014 AUA Annual Meeting, AUA; International Prostate Forum, Orlando, FL, 5/18/2014

Transitioning from Drug to Therapy Development of Prostate Cancer, 2014 AUA Annual Meeting, AUA; AUA/NCI SPORE Joint Workshop, Orlando, FL, 5/18/2014

NEPC Patient Cases, PCF-NEPC Working Group, Prostate Cancer Foundation, 5/23/2014

Lethal Prostate Cancer Variants: Neuroendocrine Prostate Cancer and Other Subtypes, 2014 ASCO Annual Meeting, ASCO; Clinical Problems in Oncology Session, Chicago, IL, 6/1/2014

From Prognostication to Prediction, 2014 Prostate Cancer Foundation Scientific Retreat, Prostate Cancer Foundation, Carlsbad, CA, 10/24/2014

Prognostic to a Predictive Model of Therapy Allocation, 2015 AUA Annual Meeting, American Urological Association, New Orleans, LA, 5/19/2015

Companion studies reflecting the spectrum in biology implicated in mCRPC, Workshop on Translational Science in Prostate Cancer, National Cancer Institute, Rockville, MD, 4/4/2016

Other, Including Scientific Exhibitions

N/A

Seminar Invitations from Other Institutions

Emerging data in mCRPC, Sanofi Prostate Cancer Clinical Evidence Generation Advisory Board, Sanofi Jevtana, San Francisco, CA, 1/29/2014

Can Advanced Prostate Cancer Be Cured?, University of Rochester Urology Colloquium, University of Rochester Medical Center, Rochester, NY, 4/16/2014

Targeting the Prostate Cancer Microenvironment, University of Rochester Urology Colloquium, University of Rochester Medical Center, Rochester, NY, 4/16/2014

Frontiers in Prostate Cancer Research, University Hospital of Larissa, Athens, Greece, 9/5/2014

Targeting Androgen Signaling, Prostate Cancer Debate Meeting, Lisbon, Portugal, 10/23/2014

Integrating Chemotherapy into the Management of Prostate Cancer, Sanofi, Boston, MA, 1/26/2015

Shift from prognostication to prediction in APC: Are we ready?, Advanced Prostate Cancer Consensus Conference, Kantonsspital St. Gallen, St. Gallen, Switzerland, 3/13/2015

New Therapies and New Strategies, Oncology Spring Meeting, Janssen Portugal, Evora, Portugal, 4/25/2015

Transitioning from a Prognostic to a Predictive Model of Therapy Allocation, Spring 2015 Seminar Series, University of Houston, Houston, TX, 4/29/2015

Transitioning from a Prognostic to a Predictive Model of Therapy Allocation, Scientific Exchange Meeting at AUA, AstraZeneca K.K. Japan, New Orleans, LA, 5/29/2015

Metabolic pathways of CRPC, Highlights in Prostate Cancer, Universita della Tuscia, Viterbo, Italy, 6/19/2015

Shifting from "drug development" to "therapy development" in prostate cancer, 3rd Pan-Hellenic Congress of the Research Urogenital Oncology Department, University Hospital of Larissa, Larissa, Greece, 9/5/2015

Bone metastases in CRPC: Pathophysiology, Survival and Quality of Life, Medscape, LLC, San Antonio, TX, 10/19/2015

Advances in the Understanding & Therapy of Prostate Cancer, Karolinska Institutet and Hospital, Stockholm, Sweden, 11/6/2015

Toward a Biological Based Allocation of Therapy in Prostate Cancer, University of Patras, Patras, Greece, 12/11/2015

Developing a strategy for the rational integration of therapies for men with prostate cancer, 7th Post-Educational Seminar of Clinical Research Oncology, Hellenic Foundation for Cancer Research, Athens, Greece, 1/23/2016

Companion studies reflecting the spectrum of biology implicated in mCRPC, National Cancer Institute, Rockville, MD, 4/4/2016

Transitioning from a Prognostic to a Predictive Model of Therapy Allocation in Prostate Cancer, University of Vermont Medical Center, Burlington, VT, 6/23/2016

Monitoring the Emergence of Resistance in Prostate Cancer to Inform a Marker-Driven Treatment Strategy, 2016 PCRP IMPaCT Conference, Department of Defense PCRP, Towson, MD, 8/4/2016

Monitoring Prostate Cancer progression to Inform Treatment Strategy, USC Dornsife, Los Angeles, CA, 9/26/2016

Perspective on novel agents (including PARP inhibitors) - What will change for men with advanced prostate cancer in the next 24 months?, Advanced Prostate Cancer Consensus Conference, Kantonsspital St. Gallen, St. Gallen, Switzerland, 3/10/2017

Lectureships and Visiting Professorships

Paradigm shifts in prostate cancer therapy, 9th W.B. Ingalls Memorial Prostate Health & Cancer Symposium, International Cancer Alliance for Research and Education, Boca Raton, FL, 1/28/2017

Other Presentations at State and Local Conferences

Seminoma (Lesson Plan). In: Directions in Oncology: A Bi-Weekly Update, Editorial Member of Nassau Publications of Princeton, NJ, 1/1/1985

Advances in the treatment of urologic cancers. In: Innovations in Urologic Practice, Postgraduate Course, Baylor College of Medicine, 2/1/1989

Prostate Cancer. In: Medical Oncology: A Comprehensive Study, Review Course in Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 10/15/1989

Testicular Cancer. In: Medical Oncology: A Comprehensive Study, Review Course in Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 10/15/1989

Therapeutic Decisions in the Treatment of Advanced Prostate Cancer (Slide/Lecture Kit), Medical Information Services, Inc. and Marrison Merrell Dow Inc., 1/1/1996

New agents in Prostate Cancer, Presented his experience in the treatment of hormone refractory prostate cancer. (Lecture/Slide), Clinical Insights Inc., Orlando, Fla, 1/1/1999

Taxotere-Specific Trials in Hormone-Refractory Prostate Cancer and Treatment of Prostate Cancer, The Prostate Cancer Advisory Board II on behalf of Rhone-Poulenc Rorer/The Right Angle, Inc, Phoenix, AZ, 1/1/1999

Clinical biology and therapy of advanced prostate cancer, The 9th International Congress on Anti-Cancer Trea, Paris, France, 2/1/1999

Human Experimentation in Prostate Cancer, The Prostate Mens Group, St. Luke Methodist Church, Houston, TX, 2/1/1999

NCCN Prostate Cancer Practice Guidelines, National Comprehensive Cancer Network 4th Annual C, Ft. Lauderdale, Fla, 2/26/1999

Integrated Approach to the Development of Therapy for Regionally Advanced Prostate Cancer, The 2nd Foundations of Clinical Cancer Research Symposium (Lecture), UTMDACC, Houston, TX, 3/1/1999

Mechanism-based therapies for prostate cancer, The Q1 Therapy Consortium Team 1 Meeting, Cap CURE (Lecture), New York City, NY, 3/1/1999

Neoadjuvant and Adjuvant Chemotherapy for Muscle Invasive Disease and Chemotherapy and Palliation for Hormone Refractory Disease, The Cleveland Clinic Urology Symposium, Ft. Lauderdale, Fla, 3/1/1999

Integration of therapy in the treatment of prostate cancer, The American Cancer Society's Science Writers Semi, Miami, Fla, 3/17/1999

Docetaxel-A New Option for the Therapy of Hormone Refractory Cancer, The Right Angle, Inc. on behalf of Rhone-Poulenc, Chicago, IL, 4/1/1999

The Challenging Cases in GU/GYN Malignancies, The Network for Medical Communication & Research, Washington, DC, 4/1/1999

Preparatory Meeting for the various committees for the 2nd International Consultation on Prostate Cancer in Paris, The AUA 94th Annual Meeting, Dallas, TX, 5/1/1999

Prostate Cancer (Poster Board Session and News Briefing), The 35th ASCO Annual Meeting (Lecture/Slides), Atlanta, GA, 5/1/1999

Testicular Tumors, The 35th ASCO Annual Meeting (Lecture/Abstract), Atlanta, GA, 5/1/1999

Management and Treatment of Advanced Carcinoma of the Prostate, The AUA 94th Annual Meeting, Dallas, TX, 5/2/1999

The Podium Session, The AUA 94th Annual Meeting, Dallas, TX, 5/4/1999

The 1999 SPORE in Prostate Research External Advis, Detroit, MI, 5/13/1999

Biology and Therapy of Advanced Prostate Cancer, The American Cancer Society/UC San Diego Colloquiu, San Diego, CA, 6/8/1999

Deposition for the Congress of the Senate, The Dirksen Bldg. On Capital Hill, Washington, DC, 6/16/1999

Neuroendocrine Markers/The Prostate Marker Meeting, Northwest Hospital-Pacific Northwest Cancer Founda, Vancouver, Canada, 7/17/1999

Advances in the Therapy of Bladder Cancer, The Baton Rouge Oncology Group, Inc., Baton Rouge, LA, 8/1/1999

Integration of Gene Therapy into the Management of Prostate Cancer, The 1999 Texas Medical Center Gene Therapy Symposium (Lecture/Slides), The Hickey Auditorium, Houston, TX, 9/1/1999

To discuss the current status of PS-341 and to plan for future phases of development, Boston, MA, 9/20/1999

Issues In Prostate Cancer (Lecture/Slides), A Conference for Patients and Families, League City, TX, 10/1/1999

The Application and Development of Novel Therapy in Prostate Cancer (Lecture/Slides), CaP CURE 6th Annual Scientific Retreat, Lake Tahoe, NV, 10/1/1999

Development of Therapy for Advanced Prostate Cancer" (Lecture/Slides)., The Chemotherapy Foundation Symposium XVII on Inno, New York City, 11/4/1999

The First State of the Science (SOTS) Workshop in Prostate Cancer, NCI, Washington, DC, 11/14/1999

CaP CURE 1999 Competitive Research Awards, Santa Monica, CA, 12/10/1999

Greater Palm Beach Prostate Cancer Forum, Palm Beach, FL, 2/11/2000

Speaker at the home of Mary and Howard Lester on Cancer Prevention, Indian Wells, CA, 2/18/2000

Chairman of the 8th Annual Genitourinary Conference, Houston, TX, 3/23/2000

GU Cancer Think Tank, San Francisco, CA, 3/30/2000

NCI Funders Conference on Prostate Cancer, NIC/NIH, Bethesda, MD, 4/1/2000
The AUA 95th Annual Meeting, Dallas, TX, 4/29/2000
Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention, Galway, Ireland, 5/12/2000
American Society of Clinical Oncology 36th Annual, New Orleans, LA, 5/20/2000
CaP CURE 7th Annual Scientific Retreat, Lake Tahoe, NV, 9/19/2000
Metastasis Session, Society for Basic Urologic Research Fall 2000 Symp, Ft. Myers, FL, 11/1/2000
Society of Urologic Oncology and Urologic Oncology Program Annual Urologic Oncology Meeting, Bethesda, MD, 12/2/2000
Yale Cancer Center Ground Rounds, New Haven, CT, 1/15/2001
Invasive Bladder Cancer – A Euro-American Encounter (debate with case), XVIth Congress of the European Association of Urol, Geneva, Switzerland, 4/1/2001
Prostate Cancer Workshop, Guadalajara, Spain, 4/20/2001
Strategy for Accelerated Development & Application of Therapy for Prostate Cancer, ASCO 2001 Meeting, San Francisco, CA, 5/12/2001
Strategy for Accelerated Development & Application of Therapy for Prostate Cancer, Menlo Circus Club, San Francisco, CA, 5/15/2001
Clinical Trials in the State of a Rising PSA, CAP CURE Meeting, New York, NY, 6/1/2001
Panelist on the topic of Practical Aspects of Bladder Cancer, Annual Urological Association Annual Meeting, Anaheim, CA, 6/1/2001
Strategy for Accelerated Development and Application of Therapy for Prostate Cancer, CAP CURE Eighth Annual Scientific Retreat, Lake Tahoe, NV, 9/1/2001
Prostate Cancer, CAP CURE Physicians Meeting, Board of Directors Meeting and Dinner meeting, New York, NY, 11/1/2001
Shifting Paradigms in Tumor Metastasis: Challenges and Research Opportunities, National Cancer Institute Workshop, Washington, DC, 11/12/2001
CAP CURE Competitive Award Review, CAP CURE, Santa Monica, CA, 12/1/2001
Interprostate SPORE Meeting, New York, NY, 1/10/2002
New Perspectives in Cancer Treatment, 1st Scientific Symposium, Thessaloniki, Greece, 1/19/2002
Chairman of the 9th Annual Genitourinary Conferenc, Houston, TX, 2/7/2002
7th Annual NCCN Conference, Hollywood, CA, 3/1/2002
Discussion at the Vintage Club, hosted by Board of Visitor Member, Indian Wells, CA, 3/8/2002
American Association for Cancer Research, San Francisco, CA, 4/6/2002
Skeletal Complications Of Malignancy, Third North American Symposium, Bethesda, MD, 4/25/2002
2nd Annual Greater Cincinnati Prostate Cancer Forum, Cincinnati, OH, 5/4/2002
Taxotere Investigators' Meeting, Orlando, FL, 5/21/2002
ASCO Meeting Course Presentation, Orlando, FL, 5/29/2002
3rd International Consultation on Prostate Cancer, Paris, France, 6/20/2002
Prostate Cancer, Board of Visitors Presentation at the Aspen Institute, Aspen Institue, Aspen, CO, 7/1/2002

External/Internal Advisory Board RCC SPORE, Boston, MA, 7/3/2002
10th SPORE Investigators' Workshop, Chantilly, VA, 7/13/2002
ICMIC/SAIRP Investigators Meeting, Bethesda, MA, 7/24/2002
University of Virginia Mellon Prostate Cancer Inst, 9/5/2002
N. Central Section of the AUA Meeting, Chicago, IL, 9/19/2002
CaP CURE 9th Scientific Retreat, Washington, D.C, 9/19/2002
23rd Annual Conference on Aging, San Antonio, TX, 9/28/2002
Grand Rounds presentation at Cedars Sinai Medical Center, Los Angeles, CA, 10/3/2002
Genentech Bio Oncology Meeting, New York, NY, 10/11/2002
Presentation at PACIOU VII Congress, Rotterdam, 10/11/2002
BOV Presentation at Incline Village, NV, 10/24/2002
Attend/Present at the 9th Prouts Neck Meeting on Prostate Cancer, Prouts Neck, ME, 11/8/2002
Participation on the External Advisory Board for the Cancer Imaging Program, Southwestern, Dallas, TX, 11/11/2002
Present at the Prostate Seminar Series, Mayo Clinic, New York, 11/24/2002
Participate in the 2002 CAP CURE Competitive Research Award Selection Process, CAP CURE, Santa Monica, CA, 12/1/2002
Participate in the InterProstate SPORE Meeting, San Francisco, CA, 12/3/2002
Participate in the National Cancer Institute Specialized Programs of Research Excellence (SPORE) in Prostate and GU Cancers, Bethesda, MD, 2/26/2003
Participate in the CAP CURE Therapy Consortium, CAP CURE, Los Angeles, CA, 3/1/2003
Participate in the International Oncology Symposium, Madrid, Spain, 3/6/2003
Participate in the Southwestern Oncology Group, San Diego, CA, 4/10/2003
Participate in the AUA Meeting, Chicago, ILL, 4/26/2003
Present at Challenging Cases in Oncology, Tulane University, New Orleans, LA, 5/1/2003
Present Grand Rounds at Roswell Park Cancer Institute, Buffalo, NY, 5/23/2003
Attend/Present at the 11th Annual SPORE Workshop Meeting, Washington, D.C, 6/8/2003
Attend the Plenaxis Strategy Meeting, New York, 6/11/2003
Attend/Present at the AACR Meeting, Washington, D.C, 7/11/2003
Participate in the Avodart Basic Science Think Tank Advisory Board, Seattle, WA, 8/22/2003
Participate in the Novartis Symposium, Washington, DC, 8/28/2003
Participate in the First International Colloquium on Endothelin and Cancer, Chicago, 9/11/2003
Participate in the AACR Panel Discussion, Phoenix, AZ, 10/29/2003
Present at the Austin Urological Association, Austin, TX, 11/4/2003
Present at the CaP CURE Therapy Consortium and Retreat, New York City, 11/9/2003
Participate in the Prostate Cancer Foundation for Competitive Awards meeting, Santa Monica, CA, 12/14/2003
Participate in Grand Rounds Lecturer, Northwestern University, Chicago, ILL, 2/14/2004
Lecture at the Institute for Drug Development, San Antonio, TX, 2/18/2004
Present at the Board of Visitors, Indian Wells, CA, 2/19/2004

Present at the Annual AUA Meeting, San Francisco, CA, 5/8/2004
Present at the ASCO Meeting, New Orleans, 6/4/2004
Present at the Prostate Cancer Endpoints Meeting, New York, 8/17/2004
Present at the AACI, AACR, ASCO Clinical Trials Retreat, Landsdowne, VA, 9/1/2004
Present Grand Rounds, Emory University, 9/29/2004
Present at the Evangelismos Hospital, Athens, Greece, 11/2/2004
Present at the SBUR Congress, Athens, Greece, 11/4/2004
Present at the Prouts Neck Meeting on Prostate Cancer, Prouts Neck, MA, 11/6/2004
Present at the AACR Prostate Cancer Conference, Fort Myers, FL, 11/17/2004
Present at the University of Massachusetts Grand Rounds, Worcester, MA, 12/7/2004
Present at the Distinguished Lecture Series, New Brunswick, NJ, 2/16/2005
Present at the 2005 Prostate Cancer Symposium, Orlando, FL, 2/18/2005
Participate in the Prostate Cancer Foundation Meeting, Palm Beach, FL, 2/25/2005
Present at the AACR Annual Meeting, Anaheim, CA, 4/16/2005
Present at Memorial Sloan Kettering Grand Rounds, New York, 4/26/2005
Present at ASCO Annual Meeting, Orlando, FL, 5/13/2005
SPORE in Prostate Cancer External Advisory Committee Meeting at Northwestern University, Northwestern University, Chicago, TX, 5/27/2005
Advances in Clinical Practice: Systemic Therapy for Metastatic/Hormone-Refractory Prostate Cancer, Urologic Oncology, U.T./M.D. Anderson Cancer Center, Urology, Houston, TX, 10/7/2005
Castration-resistant Prostate Cancer, Meet the Expert Session, American Association for Cancer Research Annual Meeting 2008, San Diego, CA, 4/13/2008
Genitourinary Medical Oncology Ongoing Research, Tony's Prostate Cancer Research, Houston, TX, 4/21/2008
Using clinical observations to inform research, Department of Cancer Biology Chalk Talk, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/21/2014
Advances in Prostate Cancer, Tex US TOO, Houston, TX, 3/10/2014
Prostate Cancer Research Update, 8th Annual Celebrity Golf Event, Tony's Prostate Cancer Research, Houston, TX, 4/28/2014
Advances in Prostate Cancer Therapies, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/16/2014
Transitioning from a Prognostic to a Predictive Model of Therapy Allocation, 2nd Annual Prostate Cancer Symposium: Targeting Lethal Disease, UT Southwestern Medical Center, Dallas, TX, 11/17/2014
Advances in Prostate Cancer Therapy, Palm Beach Educational Seminar, The University of Texas MD Anderson Cancer Center, Palm Beach, FL, 1/31/2015
Moon Shots - Prostate Cancer, GAP 2015 Conference, UTMDACC Global Academic Program, Houston, TX, 4/14/2015
Transitioning from a Prognostic to a Predictive Model of Therapy Allocation, MD Anderson Physician Advisory Board Meeting, UTMDACC Office of Physician Relations, Houston, TX, 5/6/2015
GU Medical Oncology Research Overview, Introduction to Research Opportunities, DoCM Heme/Onc 1st Year Fellows, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/14/2015

Transitioning from a Prognostic to a Predictive Model of Therapy Allocation, Focus on Prostate Cancer, Cancer Fighters of Houston, Houston, TX, 2/23/2016

Advances in Prostate Cancer, Tex US TOO, Houston, TX, 5/9/2016

Steroid Hormone Biosynthesis and Prostate Cancer Progression, Metabolism in Cancer Symposium 2016, Department of Cancer Systems Imaging, UTMDACC, Houston, TX, 9/13/2016

Toward efficacious marker informed treatment strategies, Prostate Cancer Moon Shot Conference, MD Anderson Cancer Center, Houston, TX, 1/14/2017

Prostate Cancer Research, Making Cancer History Seminar, The University of Texas MD Anderson Cancer Center, Development Office, Indian Wells, CA, 2/20/2017

Prostate Cancer Research, Making Cancer History Seminar, The University of Texas MD Anderson Cancer Center, Development Office, Indian Wells, CA, 2/21/2017

Co-Clinical Trials, Effective Therapy Strategies for Prostate Cancer by Developing a Predictive Model, Prostate Cancer International Conference, Athens, Greece, 3/6/2017

Proposed Integrated Study, Effective Therapy Strategies for Prostate Cancer by Developing a Predictive Model, Prostate Cancer International Conference, Athens, Greece, 3/7/2017

Targeting the Bone Microenvironment, Effective Therapy Strategies for Prostate Cancer by Developing a Predictive Model, Prostate Cancer International Conference, Athens, Greece, 3/7/2017

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held National and International

American Association for Cancer Research
Chairperson, Annual Meeting, 1978-1982

American Medical Association
Member, 1978-present

American Society of Clinical Oncology
Member, 1978-present

American Association for Cancer Research
Member, 2001-present

American Urological Association
Member, 2001-2009

Board of Scientific Advisors
Board Member, 2001-2011

AACR Clinical Cancer Research Committee
Member, 2003-2005

CaP CURE Foundation Board of Directors
Board Member, 2003-2008

Local/State

Harris County Medical Society
Member, 1978-present

Texas Medical Association
Member, 1978-present

Clinical Investigations Subcommittee
Member, 2003-2005

UNIQUE ACTIVITIES

N/A

DATE OF LAST CV UPDATE
1/9/2018